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Bax is an essential mediator of cell fate.  Since its discovery in 1985 as a protein 
that interacts with the anti-apoptotic protein, Bcl-2, key elements related to its function, 
structure and regulation remains to be determined.  To this end, mitochondrial 
metabolism was examined in non-apoptotic Bax-deficient HCT-116 cells as well as 
primary hepatocytes from Bax-deficient mice.  Although mitochondrial density and 
mitochondrial DNA content was the same in Bax-containing and Bax -deficient cells, 
MitoTracker staining patterns differed, suggesting the existence of Bax -dependent 
functional differences in mitochondrial physiology.  Oxygen consumption and cellular 
ATP levels were reduced in Bax -deficient cells, while glycolysis was increased. These 
results suggest that cells lacking Bax have a deficiency in the ability to generate ATP 
through cellular respiration, supported by detection of reduced citrate synthase activity 
in Bax -deficient cells.  Expression of either full length or C-terminal truncated Bax in 
Bax -deficient cells rescued ATP synthesis and oxygen consumption and reduced 
glycolytic activity, suggesting that this metabolic function of Bax was not dependent 
upon its C-terminal helix.  Expression of BCL-2 in Bax-containing cells resulted in a 
subsequent loss of ATP measured, implying that, even under non-apoptotic conditions, 
an antagonistic interaction exists between the two proteins.   
Bax is composed of nine alpha-helices.  While three of these helices have 
features of a trans-membrane region, the contribution of each domain to the apoptotic 
or non-apoptotic functions of Bax remains unknown.  To examine this, we focused on 
the C-terminal alpha-9 helix, an amphipathic domain with putative membrane binding 
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properties and discovered that it has an inherent membrane-binding and cytotoxic 
capacity.  A peptide based on the last twenty amino acids (CT20p) of the alpha-9 helix 
was synthesized and proved a potent inducer of cell death independent of any apoptotic 
stimuli.  The solubility of CT20p allowed it to be encapsulated in polymeric nanoparticles 
(NPs), and these CT20p-NPs caused the death of colon and breast cancer cells in vitro 
and induced tumor regression in vivo, using a murine breast cancer tumor model.  
CT20p caused increased mitochondrial membrane potential followed by cell death via 
membrane rupture, without the characteristic membrane asymmetry associated with 
apoptosis.  Hence, while CT20p is based on Bax, its innate cytotoxic activity is unlike 
the parent protein and could be a powerful anti-cancer agent that bypasses drug 
resistance, can be encapsulated in tumor-targeted nanoparticles and has potential 
application in combination therapies to activate multiple death pathways in cancer cells.  
While previous work revealed novel aspects of the biology of Bax that were 
unrecognized, new structural information is needed to fully elucidate the complexity of 
Bax’s function.  One approach is to use computational modeling to assess the solved 
structure of Bax and provide insight into the structural components involved in the 
activity of the protein.  Use of molecular dynamics simulators such as GROMACS, as 
well as other computational tools provides a powerful means by which to test the 
feasibility of certain modifications in defined parameters.  Such work revealed that the 
removal of the C-terminal alpha-9 helix of Bax, which normally resides within a 
hydrophobic pocket, significantly destabilized the protein, perhaps explaining how the 
protein transitions from soluble to membrane-bound form and maintain energy 
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production via aerobic respiration or, conversely, how the C-terminus helix conveys 
cytotoxicity.  Collectively, this work reveals that Bax is more than an inducer of cell 
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CHAPTER 1: GENERAL INTRODUCTION 
At a cellular, tissue, and organism level, the balance between life and death is a 
highly complex system that operates on a very simple premise: it is better to die than to 
be wrong [1].  This is particularly true at the cellular level where the cell is forever 
deciding whether to skew its resources towards proliferation, differentiation or 
apoptosis.  A substantial effort has been made to determine the specific initiators and 
mechanisms of, particularly, the intrinsic apoptotic pathway.  This highly regulated and 
predictable series of events that result as the pathway propagates provides an excellent 
opportunity to determine the specific contribution of each player in the apoptotic 
cascade.  Central to the intrinsic apoptotic pathway are the mitochondria and the 
proteins that interact with mitochondrial membranes.  The understanding of the interplay 
between the pro- and anti-apoptotic proteins allows for a better design of activators or 
inhibitors to force the cell into a particular fate.  This becomes highly desirable in 
disease states such as cancer, as any defects in the genetic or protein expression 
within the apoptotic machinery can push the cell into uncontrolled proliferation, 
immortality, and subsequent carcinogenesis [2].   
Apoptosis 
Maintaining the balance between life and death within a cell are the B-cell 
Lymphoma 2 (Bcl-2) family of proteins.  This family, of which Bcl-2 is the founding 
member, is comprised of both pro- and anti- apoptotic members and shares a number 
of common features [3].  These features include, but are not limited to, helix-turn-helix 
tertiary structure and Bcl-2 homology (BH) functional domains [4] (Figure 1).  These 
 
2 
characteristic features allow for both synergistic (ex. tBid – Bax) and antagonistic (ex. 
Bcl-2 – Bax) interactions, which then act as determinants of cell fate.  Additionally, a 
majority of these proteins have the ability to target the mitochondrial membrane 
specifically, and contain trans-membrane domains [5].  The ability of these proteins to 
target the mitochondria with prejudice is integral to their function as homeostatic 
regulators or death inducers.  Since mitochondria are the energy generators of the cell, 
in terms of aerobic respiration and adenosine triphosphate (ATP) production, 
maintenance of mitochondrial integrity is paramount for cell survival [6].  Under non-
apoptotic conditions, the effects of the pro-apoptotic proteins are offset by the presence 
of anti-apoptotic Bcl-2 and BclXL at the outer mitochondrial membrane.  An imbalance of 
this interaction will push the cell toward either death (Bax > Bcl-2) or survival (Bax < Bcl-
2) [7]. 
The caspase-mediated apoptotic process can be set into motion by either an 
extrinsic or intrinsic signal. In addition to these processes, a non-caspase mediated 
pathway involves the activation of Apoptosis Initiating Factor or AIF [8], [9].  The 
extrinsic process is activated by the engagement of death ligand, most commonly 
Tumor Necrosis Factor (TNF) or FasL receptors [8].  The resultant pathway involves 
intermediate proteins TNF receptor associated death domain (TRADD) and/or Fas 
associated death domain (FADD) in the activation of caspases 8 and 3.  In a slightly 
more complex manner, the initiation of the intrinsic death pathway instigates a series of 
events that allow for the release of apoptotic peptidase activating factor 1 (apaf-1), 
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cytochrome c, and pro-caspase 9 [8].  The subsequent assembly of the apoptosome 
results in the activation of effector caspases that lead to cell death (Figure 2).   
Central to the intrinsic pathway is the capability of the pro-apoptotic subset of 
Bcl-2 proteins (Bax, Bid, Bak, and Bad) to target the mitochondria.  Bcl-2-associated 
protein X (Bax) contains within its primary sequence a mitochondrial targeting sequence 
that, when exposed, directs the protein to the outer mitochondrial membrane [10].  Once 
there, Bax acts as a direct competitor with Bcl-2.  The identification of orthologs of the 
BAX gene throughout mammalian genomes indicates the evolutionary conservation of 
the protein is necessary for survival of the organism, even though no ortholog has been 
identified in Caenorhabditis elegans [11].  Differential tissue expression of Bax during 
embryogenesis promotes normal retinal, renal tube and kidney development.  
Conversely, Bax is down-regulated during the development of the nervous system [12–
14].   
Structurally, Bax retains the helical packing of other Bcl-2 family members, and of 
the four BH domains common to Bcl-2 proteins, Bax has three (BH1, 2, 3) [15] (Figure 
1).  Unlike Bcl-2 or BclXL, which are both membrane bound, Bax exists in two 
conformations: 1) a soluble, monomeric, “inactive” form, and 2) a membrane-bound, 
oligomeric, “active” form [16].  The solved solution NMR structure yields some insight 
into how the protein is able to transition from the inactive to the active form.  Bax is 
comprised of nine -helices of which two ( and ) are hydrophobic, and 9 is 
amphipathic, with these three helices containing the putative pore forming and 
membrane insertion domains of the protein [17].  As long as Bax remains cytosolic, 
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these domains are obscured from the environment and cannot interact with the 
mitochondrial membrane.  Upon activation of the intrinsic apoptotic pathway, the protein 
undergoes a conformational change resulting in relaxation of the tertiary structure, 
exposing the domains and allowing for interaction with the membrane. 
Though the exact mechanism of oligomerization is not clear, it is known that 
translocation of Bax from the cytosol to the outer mitochondrial membrane directly 
results in the release of apoptotic factor cytochrome c and activation of caspase 9 [18], 
[19].  The pore-forming capability of this oligomerization event also destabilizes the 
outer mitochondrial membrane causing a decrease in membrane potential, a release of 
Ca2+, and resulting in a series of events such as mitochondrial fragmentation and 
phosphatidylserine (PS) flipping [20–22].  These events are predictable, measureable 
consequences of Bax activation.  However, despite the fact that numerous studies have 
isolated, truncated, and mutated various domains of the protein, it remains to be 
determined which domains of Bax are necessary for it to execute its apoptotic function.   
Bcl-2 proteins in Metabolism 
The idea that the Bcl-2 family members can be compartmentalized into strictly 
pro- and anti-apoptotic roles is limiting to the scope in which these proteins act.  Bad, for 
example, canonically characterized as a pro-apoptotic protein, acts as a shuttle for 
hexokinase 4 to the mitochondria under non-apoptotic conditions [23], [24].  BclXL 
interacts with the F1FO ATP synthase to increase the efficiency of proton transport in the 
mitochondria of neurons [25].  Similarly, Bid has a critical role in the inflammatory 
response that is independent of its apoptotic function [26].  These, and other 
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observations, indicate that the cell can utilize the organelle targeting capability of Bcl-2 
proteins to execute homeostatic functions.  Similarly, cyctochrome c, a component of 
the apoptosome, functions primarily as an electron shuttle between complex III 
(Coenzyme Q-Cyt c reductase) and complex IV (Cyt C oxidase) [27].  The ability of pro-
apoptotic proteins to affect membrane permeability and even to associate with voltage 
channel component proteins indicates that any potential regulatory role is equally as 
important as the apoptotic activity. 
The link between metabolism and cancer was first identified by Otto Warburg in 
what known as the Warburg effect [28].  The Warburg effect links a switch from 
oxidative phosphorylation to aerobic glycolysis with carcinogenesis.  Since the 
mitochondria is, in essence, the power generator of the cell, the maintenance of 
oxidative phosphorylation (OXPHOS) is necessary to ensure that the cell has sufficient 
levels of ATP for cell homeostasis and growth [29].  OXPHOS is facilitated by a series 
of protein complexes housed in the inner mitochondrial membrane (IMM).  These 
proteins shuttle electrons from donors to acceptors along a chemiosmotic gradient 
within the electron transport chain (ETC) (Figure 3).  This gradient has both a pH and 
electrical component that is potentiated across the IMM, and acts as the driving force for 
the F1FO ATP synthase that terminates the ETC.  The status of the mitochondrial 
membrane potential () is indicative of viability of the cell and is maintained by a 
series of regulators at the OMM (as reviewed in [30]).  The electrochemical potential 
across the IMM is 180 mV, which renders the matrix facing membrane negatively 
charged, is due in part to the presence of a lipid unique to the mitochondria, cardiolipin 
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[31]. Cardiolipin is unique in that it has two negative charges and is found acting as a 
proton trap in the IMM, surrounding the protein complexes in the ETC, and maintaining 
the impermeability of the IMM [32]. Increased electro-negativity of the OMM can be 
linked to an increased exposure of cardiolipin, an event that is an early indicator of 
apoptosis and a precursor to depolarization of the IMM [33].  While this is not the point 
of no return in the apoptotic cascade, the electro-negativity conferred by the exposed 
cardiolipin is sufficient to attract cationic proteins, particularly Bax with its cationic trans-
membrane tail.   
Protein complexes such as Voltage Dependent Anion Channels (VDAC) and 
ADP/ATP translocases like the adenine nucleotide translocators (ANTs) serve to 
maintain the overall integrity of the mitochondria by regulating ion and mitochondrial 
ATP flux, ultimately maintaining the [34].  The component proteins of these 
permeability transition pores (PTP) [35] contain known and putative binding partners of 
Bax.  While Bax is predominantly cytosolic in its inactive form, it has been reported that 
even in non-apoptotic conditions, a fraction of the existing protein can be found 
associated with these candidate binding partners.  Additionally, the transient negative 
charge on the OMM could act as an attractant for the positive charge localized within 
the trans-membrane region of Bax.  The localized and transient interaction of Bax with 
the OMM and its resident proteins would account for a homeostatic, regulatory role for 
the protein.   
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Bax in therapeutics 
The manipulation of Bcl-2 family proteins in the treatment of cancers has been 
studied for many years.  Over-expression of Bcl-2 is common in a number of cancers, 
and often leads to resistance to traditional chemotherapies because of the overriding 
survival signal conveyed by the protein [36].  To combat this, oligonucleotide therapy 
targeting gene expression and small molecule inhibitors, such as ABT-737, targeting 
protein function [37–40] has been developed to mitigate the effects of over-expressed 
Bcl-2.  Conversely, inducible activation of pro-apoptotic proteins, like Bax, would render 
a cancerous cell susceptible to a secondary treatment, if not kill the cell outright [41].   
To this end, analysis of the structure and apoptotic function of Bax and its 
domains provides an insight into the derivation of novel small molecule therapeutics.  
The pore-forming capability of Bax is well documented, with helices 5,6 and 9 being 
putative membrane spanners [17].  There are a number of theories as to how the 
protein docks within the membrane, including an umbrella model [42], which involves 
unfolding of the protein once interfaced with mitochondrial membrane.  However, an 
examination of the composition of the helices reveals that the 9 helix shares a striking 
similarities to anti-microbial peptides (AMPs); these peptides tend to be amphiphilic in 
nature with localized cationic residues and hydrophobic regions [43].   
Peptides and small molecules provide a promising pool of candidates for potent 
cancer therapy.  These peptides and small molecules are currently being developed, 
with some in clinical trials (Table 1) to either serve as targeting agents (RGD peptide) 
[44], cell permeabilizers (CPPs) [45], or cell penetrating peptides (TAT) [46] (Figure 4).  
The exploitation of a peptide derived from the mitochondrial localization region of Bax 
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would provide a novel peptide therapy for treatment of certain cancers.  With the 
mitochondria, as the power generator of the cell, it is an ideal drug target.  Additionally, 
contained within the mitochondrial matrix, and even bound to the IMM itself are factors 
that could push the cell into an apoptotic or even a necrotic fate.  Targeting the 
organelle, itself, instead of a receptor or pathway makes it very difficult for the cell to 
engage a redundant mechanism, minimizing off-target effects.   
A determination of the membrane disruption capabilities of the membrane 
targeting region would provide insight into the development novel therapeutic derived 
from Bax.  The pore-forming capabilities of classical, cationic AMPs fall into two 
categories: barrel-stave and toroidal pores [47] (Figure 5).  Previous studies examining 
the orientation and assembly of the Bax derived CT20p in model membranes by solid 
state NMR indicate that the peptide does indeed assemble in a membrane in an anti-
parallel arrangement to form a pore (Tatulian, SA, et al. submitted) (Figure 6).  
Evaluation of the cytotoxic properties of this peptide also yields information on the ability 
of the protein as a whole to self-regulate in the absence of an apoptotic stimulus.   
Computational modeling and Protein expression 
Since the discovery of the bcl-2 gene to convey immortality to pre-B cells in 1988 
[48], a significant amount of research has been dedicated to the understanding of the 
interplay of the Bcl-2 family and the roles they play in promoting or inhibiting the 
progression of apoptosis.  Surprisingly, insights into the functions and mechanisms of 
action are few and far between.  Bax is a prime example of the difficulty in 
characterizing the fine details of the dynamic nature of these proteins.  An examination 
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of the literature describing the functional domains places the “killer” or membrane 
interacting regions at the N-terminus [49], the helices [50], or the C-terminus 
[51]  There is no true consensus on the regions that contribute to oligomerization, 
however, a BH3 binding groove can be targeted to activate the protein [52].  This is due 
in part to the relative difficulty of studying the protein in an isolated state.  There is, to 
date, one solved NMR structure of the protein in its entirety, unbound to any other 
peptide, antibody or protein fragment [10].  This lone structure is the basis of in silico 
modeling that drives drug design geared to activation of the protein.   
What is largely absent from the literature is the utilization of molecular dynamics 
in silico to assess the internal dynamics of Bax. The ability to measure a protein’s 
behavior after the application of a series of defined physical constraints provides 
valuable insight into the mechanisms of action of proteins of interest.  Computational 
modeling allows for the generation of environments that simulate the behavior of a 
molecule, protein, or complex under a specified set of conditions.  Analysis post 
simulation supplies information on the folding, mechanism of action, and interacting 
sites under those conditions.   
Modeling of members of the Bcl-2 family allows for directed design of inhibitors of 
certain proteins.  Most of the 30 identified family members have been solved either by 
NMR or by X-ray crystallography [53].  The highly conserved structural homology within 
the Bcl-2 family lends itself for comparative studies among the constituent proteins.  For 
Bax to transition from the cytosol to the mitochondria, a relaxation of the structure is 
required to expose domains capable of interacting with a lipid membrane.  This requires 
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some level of self-regulation by the protein, and measurements taken on the isolated 
model gives a step-wise look at the ordered reorganization, unfolding, or exposure of 
specific domains.  Molecular dynamics simulations provide a high throughput means to 
determine the effects of mutations or deletions on the structure, energy and packing 
density on the protein.   
The work presented here takes an interdisciplinary approach to examine the 
structure and function of Bax and its constituent domains.  An examination of the 
behavior of Bax in non-apoptotic conditions uncovered a previously undescribed role for 
Bax in the maintenance of the bioenergetics in the cell.  Comparison of the primary 
sequence of the -helix to known anti-microbial peptides led to isolation of the last 20 
amino acid residues, and the discovery of a potent cytotoxic agent.  These observations 
together prompted a series of computational simulations to help elucidate the regulatory 
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Figure 1.  Representative Members of the Bcl-2 Protein Family 
The Bcl-2 family members divided into three subgroups: anti-apoptotic proteins which include Bcl-2, Bcl-
XL, and MCL-1 among others, pro-apoptotic proteins Bax, Bak, and Bok, and BH3 only pro-apoptotic 





Figure 2.  Caspase Dependent Apoptotic Signaling Pathways. 
The apoptotic mechanism can be initiated in one of two ways:  the intrinsic pathway, which engages the 
Bcl-2 family members and involves mitochondrial membrane disruption resulting in the release of 
apoptotic factors such as cytochrome C and pro- caspase 9.  The second pathway is the Extrinsic 
pathway which involves activation of death receptors on the cell surface by their respective ligands.  The 







                   
 
Figure 3.  The Electron Transport Chain. 
The electron transport chain operates on the combination of a chemiosmotic gradient and an electric 
potential.  The five component complexes reside in the IMM and use the transfer of electrons to pump 







Figure 4.  Classes of Therapeutic Peptides. 
Current therapeutic peptides can be classified into three major divisions.  A) Antimicrobial peptides (i.e. 
magainins or cecropins) or “pore forming” peptides (i.e. derived from the Bcl-2 family of apoptosis 
mediators) are targeted to characteristics of certain membranes and typically incorporate into the 
membrane to form toroidal pores, affecting both membrane stability and membrane potential.  B) Cell 
permeable peptides, for example the Tat peptide derived from HIV, are usually arginine rich and inert to 
the cell.  They do not require an endocytotic mechanism to incorporate in the cell, and are often tethered 
to another more active compound or peptide that, making this a “Trojan horse” class.  C) Targeting 
peptides, such as RGD or NGR peptides, are specific for a plasma membrane component overexpressed 
by the tumor vasculature.  These peptides are typically used to target a secondary chemotherapy agent 











Figure 5.  Schematic of pore types. 
The models of the (A) barrel-stave and (B) toroidal pores were generated using SketchUp (Google).  The 
















Figure 6.  Model for the membrane pore formed by the CT20p. 
Left: Peptide molecules are shown in ribbon format, colored according to peptide monomer. The 
secondary structure, orientation of strands and helices, and tryptophan insertion into the membrane are 
based on polarized ATR-FTIR and fluorescence quenching data. Right: Top view of the pore formed by 
CT20p is shown in a CPK format, colored according to peptide monomer. A calcein molecule is shown 
within the pore in a ball and stick format.  
 




CHAPTER 2: BAX SUPPORTS THE MITOCHONDRIAL NETWORK, 
PROMOTING BIOENERGETICS IN NON-APOPTOTIC CELLS 
Introduction 
 An understanding of the apoptotic process has revealed that many of the 
important mediators, such as cytochrome c, can have dual roles: a non-apoptotic 
function and an apoptotic function [27].  The non-apoptotic roles of such proteins can 
range from contributing to energy production [27] to maintaining pH homeostasis [54].  
During apoptosis, these proteins’ housekeeping functions are subverted committing the 
cell to a death program.  When first discovered, the members of the B-Cell Lymphoma 
(BCL-2) family of apoptotic modulators were presented as regulators of cell death [55], 
and the detrimental effects upon their deletion were attributed to loss of their apoptotic 
activity [56], [57].  While these proteins remain critical effectors of apoptosis, recent 
findings suggest that functional duality may also exist for multiple BCL-2 proteins. 
Conventionally, the Bcl-2 family is segregated into two sub-groups: pro- and anti-
apoptotic proteins.  Each of the proteins in this family shares at least one and up to four 
Bcl-2 homology domains (BH1-4) [58], [59].  The anti-apoptotic group includes such 
proteins as Bcl-2, Bcl-XL and MCL-1.  Pro-apoptotic proteins include the multi-domain 
proteins, Bax and BAK, and the BH3-only proteins Bim, Bad, and Bid [15].  The solved 
NMR structure of Bax revealed a globular structure with nine helices [10].  Residues 
from the 2, 3, 4, and 5 helices, which encompass part of the protein’s BH3 
domain, arrange to form a prominent hydrophobic groove.  In its cytosolic state the C-
terminal 9 helix of Bax, a putative trans-membrane domain, occupies this hydrophobic 
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groove [10].  Although the apoptotic roles of these Bcl-2 family members are the focus 
of much research, only a small number of non-apoptotic functions have been described.  
The BH3-only protein, Bad, was reported to complex with hexokinase 4 in order to 
regulate intracellular glucose metabolism in non-apoptotic hepatocytes [23].  Bcl-2 was 
shown to modulate cell cycle progression [60], [61].  Bax was found to affect the 
production of reactive oxygen species (ROS) by the mitochondria in non-apoptotic 
neurons [62], and the absence of Bax and Bak in T cells altered Ca2+ release resulting 
in a defect in antigen-specific proliferation [63].  These findings are intriguing and 
suggest that possible non-apoptotic activities of the Bcl-2 family merit further 
examination. 
Current studies on the apoptotic activity of Bax revealed many interesting 
features that enable the protein to transition from a soluble, cytosolic form to a 
membrane-bound form. But do these same features enable Bax to have a non-apoptotic 
function?  While Bax is known as a tumor suppressor, it is mutated but rarely completely 
ablated in certain types of tumors [64], suggesting that the complete loss of all function 
could be detrimental.  As an example, HCT-116 colorectal cells were treated with a 
mutagen to produce cells deficient in Bax with the result that only 4% of the cells had 
two mutant BAX alleles (-/-), while 94% mutated one allele (+/-) [65].  Studies of Bax 
deficient mice revealed conflicting results, the loss of Bax produced either hyperplasia 
or hypoplasia in a tissue-specific manner [66]. These data indicate that Bax may have 
an unrecognized activity in healthy, normal cells. To study this, we examined 
mitochondrial bioenergetics in Bax-containing (Bax+/+) and Bax-deficient (Bax-/-) HCT-
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116 cells as well as hepatocytes from Bax-deficient or wild-type mice.  We found that in 
Bax-/- cells intracellular ATP and aerobic respiration was significantly reduced, while 
glycolysis was increased.  We inferred that a small amount of mitochondrial-associated 
Bax was needed to support cellular respiration.  We thus describe a novel non-apoptotic 
activity of Bax that sustains mitochondrial metabolism and could mitigate the complete 
loss of the protein by a tumor cell. 
 
Materials and methods 
Cell Lines and Reagents. 
Bax+/+ and Bax-/- HCT-116 colorectal cancer cell lines (a kind gift from Dr. Bert 
Vogelstein, John Hopkins University) were grown and maintained in McCoy’s 5A 
Medium (Gibco), 10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin.  
FCCP (carbonyl cyanide-p-trifluoro-methoxyphenylhydrazone) (Sigma) was used at a 
concentration of 5 M as described below.  This was determined this to be the optimal 
concentration after performing a titration experiment (FCCP 0-25 μM) and measuring 
effects on cell viability and ATP production as described below. 
Isolation of Primary Mouse Hepatocytes. 
Hepatocytes were isolated from the livers of adult Bax knock-out (KO) and wild 
type (WT) C57BL6 mice (Jackson Labs).  The livers were perfused with Ca2+ free Krebs 
buffer by inserting a cannula into the hepatic portal vein, severing the inferior vena cava 
and injecting buffer to flush red blood cells from the liver.  The buffer was injected at a 
constant flow rate of 700L/min for 10 minutes using a syringe pump (ColeParmer).  
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After 10 minutes perfusion, the caudate lobe was removed for sectioning and the livers 
were then perfused with PBS/ 5% collagenase (MPBiomedicals) for 10 minutes or until 
the tissue became spongy.  The isolated tissues were then run through 0.2 m cell 
strainer (BD Biosciences) with ice cold Krebs buffer and residual red blood cells 
eliminated by osmotic lysis.  The cells were then washed 3 times in Krebs buffer to 
remove any residual collagenase.  Isolated hepatocytes were re-suspended in DMEM, 
10% FBS, 1% pen-strep and assayed immediately. 
Plasmids, Mutagenesis, and Transfection. 
PCR-directed deletion of the C-terminus of Bax to generate the C-terminal 
truncated form of Bax (Bax-CT) was performed using untagged primer sets and was 
confirmed by sequencing.  Bax was PCR amplified from the template, pEGFP-Bax (a 
gift from Dr. Richard Youle, NINDS, NIH).  To examine the transient expression of both 
the full length (Bax-FL) and Bax-CT recombinant Bax constructs, bi-cistronic 
ProteoTuner vectors (CloneTech) containing Bax insert and green fluorescent protein 
(GFP) separated by an internal ribosome entry site (IRES) were transfected into Bax-/- 
HCT-116 cells.  Expression of the Bax construct was induced upon the addition of 
Shield (CloneTech) at a concentration of .  The plasmid DNA was delivered at a 
concentration of 1 g/mL using the TransIT-LT1 transfection reagent (Mirus) following 
manufacturer’s protocol.  Transfection efficiency was determined microscopically by 
visualizing GFP expression after 18 hours, and ranged from 50-70%.  Experiments were 
performed within defined timeframes to ensure optimal cell viability, prior to any 




Bax+/+ and Bax-/- HCT-116 cells were cultured in RPMI, without glucose, 
containing 10% FBS, 1% Penicillin-Streptomycin. FCCP (carbonyl cyanide-p-trifluoro-
methoxyphenylhydrazone) (Sigma) was used at a concentration of 5 M.  DIC images 
for visualization of the effects of glucose deprivation were obtained with a Nikon Eclipse 
TE200 microscope using a 20x PH1 objective. The images are representative of 2 
separate experiments. 
Measurement of Oxygen Consumption and Extracellular Acidification 
Rates.  
Bax+/+ and Bax-/- HCT-116 cells, as well as isolated hepatocytes, were cultured in 
a BD Oxygen Biosensor plate at a concentration of 50,000 cells per well.  The biosensor 
plate contained an oxygen-sensitive dye embedded in a gas-permeable matrix.  Based 
on the properties of this dye, oxygen quenches the ability of the dye to fluoresce.  The 
dissolved oxygen in the media is depleted by the cells metabolizing in the well, resulting 
in an increase in fluorescence.  This allows a correlation of the rate of oxygen 
consumption to be made.  The plate was read at 37ºC on an EnVision plate reader 
(PerkinElmer) using ex/em wavelengths of 485/630nm.  Fluorescence intensity was 
measured every hour for 24 hours.  For comparisons of Oxygen consumption rates 
(OCR) and extracellular acidification rates (ECAR), Bax+/+ and Bax-/- HCT-116 cells 
were seeded at 40,000 cells/well in a 24 well Seahorse cell culture plate.  Full-length 
and CT Bax constructs were transfected into Bax-/- cells for measurement as well.  The 
transfected cells were treated with shield 3 hours prior to reading to induce expression 
 
23 
of the protein.  Measurements were taken on the Seahorse XF24 plate reader 
(Seahorse Bioscience).  Values were normalized as changes relative to the initial 
reading. 
Mitochondrial Staining: Fixed Imaging, Live Cell Imaging and Tissue 
Sectioning. 
For fixed cells, Bax+/+ HCT-116 cells were plated onto coverslips coated with 
10g/mL laminin (Invitrogen).  Cells were plated at a density of 50,000 cells/well and 
were fixed by methanol fixation.  The cells were then probed with anti- Bax (N-20; Santa 
Cruz) and anti-HSP60 (H-300; Santa Cruz) antibodies, followed by FITC and CY3 
secondary antibodies.  Images were scanned using the LSM 510 (Zeiss) with a 
100x/1.4 plan-apochromat objective. The scanned image was processed using the Zen 
2009 software (Zeiss).  For live cell imaging, Bax +/+ and Bax -/- HCT-116 cells were 
grown and plated in 24-well glass bottom dishes (MatTek) that had been pre-treated 
with 1N HCl and coated with10g/mL laminin.  The cells were plated at 10,000 cells per 
well and allowed to grow over night.  Bax -FL or Bax -CT constructs were transfected 
using the TransIT-LT1 transfection reagent (Mirus) and expressed as previously 
described.  At 18 hours post-transfection, cells were incubated with 1M MitoTracker 
Red 580 or 5M 10-Nonyl Acridine Orange (NAO) (Molecular Probes) in McCoy’s 
complete media for 30 minutes prior to imaging.  Treatments with 5M FCCP were done 
15 minutes prior to imaging.  For cells treated with Mdivi 1 (Biomol International), an 
inhibitor of DRP1 and mitochondrial fission, the cells were treated with a 
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concentration in McCoy’s complete media for 4 hours prior to the addition of 
MitoTracker. 
The caudate lobes of Bax knock-out and C57BL6 mice were frozen and 
sectioned using a Leica CM 1850 cryostat.  Tissues were cut into 12m sections.  The 
sections were rehydrated with PBS then stained with either 1M MitoTraker Red or 5M 
NAO. 
Fluorescent images were acquired with the UltraView spinning disc confocal 
system (PerkinElmer) with AxioObserver.Z1 (Carl Zeiss) stand, and a Plan-Apochromat 
63x/1.4 Oil DIC objective.  Z-stack projections of the scanned images were generated 
and modified within the Volocity image processing program (PerkinElmer).  
Sub-cellular Fractionation and Immunoblotting. 
Bax +/+ and Bax -/- HCT-116 cells were plated in 75cm2 flasks and grown to 70-
80% confluence.  Cells were transiently transfected with the Bax -FL or Bax -CT 
constructs and protein expressed as previously described.  At 18 hours post 
transfection, the cells were lifted and pelleted.  The pellets were re-suspended and 
lysed according to the protocol from the Mitochondrial Enrichment Kit (Pierce).  Note 
that a low speed centrifugation step in the mitochondrial enrichment process ensures 
that only intact and non-fragmented mitochondria are isolated.  The enriched 
mitochondria were layered on an iodixanol gradient (6%, 10%, 15%, 20%, 23%, and 
27%) and subjected to ultracentrifugation using an Optima L-100XP Ultracentrifuge for 2 
hours at 145,000 rcf in a SW55.1 swing bucket rotor (Beckman Coulter).  After 
centrifugation, each sample was unloaded in 500L fractions using a fraction recovery 
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system (Beckman Coulter), and washed in ice cold PBS twice (18,000 rcf, 30 minutes) 
to remove residual iodixanol.  The pellets from each of these fractions were re-
suspended in 1x loading buffer and run on 8-16% Tris-glycine gradient gels (Invitrogen).  
The gels were transferred to PVDF membranes and probed with primary antibodies to 
Bax (N-20; Santa Cruz), Prohibitin (ABCAM), and GRP78 (Santa Cruz), followed by 
incubation with the appropriate HRP conjugated secondary antibodies (Santa Cruz, Cell 
Signaling) and developed by chemiluminescence (Pierce). 
Proteinase K Digestion of Membrane Bound Proteins. 
Bax +/+ and Bax -/- HCT-116 mitochondria were isolated as above.  The 
mitochondria were then treated with Proteinase K (Sigma) (10 g/ml) for 5, 10, 15 or 20 
minutes in order for the outer mitochondrial membrane associated proteins to be 
digested.  The reaction was terminated with phenylmethylsulfonyl fluoride (PMSF) [67].  
The mitochondria were then washed with isotonic buffer, pelleted, re-suspended in 1X 
sample buffer, and run on 12% poly-acrylamide gels in parallel with untreated 
mitochondria. The gels were then transferred to PVDF membranes which were then 
probed with anti- Bax (N-20; Santa Cruz), as well as anti-BclXL (2762, Cell Signaling) 
primary antibodies, followed by incubation with anti-mouse or anti-rabbit IRDye 800CW 
secondary antibodies (Licor).  The membranes were imaged using the Licor Odyssey 
Infrared Imaging system. Densitometry measurements were made using Image J. 
Measurement of ATP production and Mitochondrial Membrane Potential. 
Cells were seeded and treated in 24 well plates overnight.  The cells were then 
lifted, counted and seeded in black 96 well flat-bottom plates at a density of 4,000- 
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5,000 cells/well.  To uncouple oxidative phosphorylation, 5M FCCP was added to the 
cells two hours prior to analysis of ATP concentration.  ATP levels were quantified using 
the ATPLite 1-Step assay kit (PerkinElmer).  Luciferase activity, reported as Relative 
Luminescence Units (RLU), was measured on an EnVision (PerkinElmer) plate reader.  
The luminescence was normalized to the number of cells/well.  Additionally, a standard 
curve of known ATP concentrations was established to ensure that the experimental 
values were within the detectable range of the assay.  Background signal was corrected 
for by subtracting the RLU values of an empty plate.  In addition, as the fluorescence of 
MitoTracker Red 580 (Invitrogen) is a result of oxidation of the compound within the 
mitochondrial matrix, changes in MitoTracker fluorescence intensity was used to assess 
the qualitative and quantitative efficiency of the electrochemical potential (the relative 
oxidative capability of actively respiring mitochondria) [68]. 
Measurements of mitochondrial content, membrane potential, and viability were 
done by staining the cells with both ethidium bromide (Fisher Scientific) and NAO [69].  
Briefly, 500,000 cells/sample were stained with 25ng/mL NAO and 40ng/mL ethidium 
bromide for 10 minutes.  The cells were then washed 3 times with 0.1% BSA in PBS at 
4ºC for 10 minutes at 1000 rcf.  The cells were read using the C6 flow cytometer 




Measurement of Citrate Synthase Activity. 
Isolated mitochondria from Bax +/+and Bax -/- HCT-116 cells, as well as primary 
hepatocytes from Bax KO and C57BL6 mice were assayed for  citrate synthase activity.  
The citrate synthase enzyme catalyzes the reaction: 
CoA-SH+DTNB TNB+CoA-S-S-TNB 
The rate of TNB formation is linear and has a measurable absorbance at 412nm.  
The rate of TNB generation (μMol/ml/min) was measured by spectrophotometry 
(Beckman Coulter SD8000) for 200 seconds.  Mitochondrial samples were run in Tris 
buffer to determine inner mitochondrial membrane integrity (reported as % ruptured 
mitochondria), or Tris buffer with Triton X-100 to determine citrate synthase activity. 
Inhibition by siRNA. 
Bax containing HCT-116 or lung cancer cells were seeded at a density of 
200,000 cells/well in 6 well plates.  After 24 hours, the cells were treated with 1M Bax 
SMART pool siRNA (Dharmacon) using the Accell delivery reagent (Dharmacon) for 72 
hours, following the manufacturer’s protocol.  Briefly, SMART pool siRNA combines four 
different siRNAs to reduce off-target effects, negating the need to test scrambled or 
control Bax siRNA sequences; however as a control a non-targeting siRNA was used to 
treat the cells, showing no measurable effect as compared to the Accell reagent alone.  
Delivery efficiency and siRNA non-targets effects were previously tested using Accell 
fluorescent (Cy3) non-targeting control siRNA (Dharmacon). 
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Measurement of Mitochondrial DNA.  
DNA was isolated from Bax +/+ and Bax -/- HCT116 cells using TRIZOL Reagent 
(Invitrogen) followed by ethanol precipitation.  Re-suspended DNA pellets were 
analyzed for nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) content.  Primers 
for the detection of the nuclear housekeeping gene -actin and for the mitochondrial 
DNA encoded ATPase (MTATP) 8 gene were as follows: -actin (forward): 5’-GAA ATC 
GTG CGT GAC ATC AAAG; (reverse): 5’-TGT AGT TTC ATG GAT GCC-ACAG.  
MTATP (forward): 5’-AAT ATT AAA CAC AAA CTA CCA CCT ACC; (reverse): 5’-TGG 
TTC TCA GGG TTT GTT ATA [70]. The PCR was carried out in a 7500 Fast real-time 
PCR system (Applied Biosystems).  All reactions were carried out in 20μl of total 
reaction volume containing 1μg/μl total DNA, appropriate primers and Fast SYBR Green 
Master Mix (Applied Biosystems).  Each reaction underwent a 30s 90ºC denaturation 
followed by 40 cycles of 30s at 60ºC then 3s at 95ºC.  All samples were analyzed in 
triplicate. The relative amount of mtDNA (normalized to nuclear content) is represented 
as 2ΔCt, calculated using the following equation:  
ΔCt = (CtmtDNA /CtnDNA) - (CtnDNA/CtnDNA),  
where Ct is the cycle threshold for each condition. 
Surface Plasmon Resonance (SPR) binding experiments.  
Recombinant BCL-2, Bax -FL and Bax -CT were generated using the Human In 
Vitro Protein Expression Kit for DNA Templates (Pierce).  A SR7000DC (Reichert) dual 
channel SPR and SR7000 gold sensor slide (Reichert) with a surface composition of 
10% COOH-(PEG)6-C11-SH, 90% OH-(PEG)3-C11-SH were used to test the binding 
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affinities of Bax -FL and Bax -CT to BCL-2.  Either Bax -FL or Bax -CT was 
covalently linked to the sensor slide at a concentration of 1.4g/mL at a flow rate of 
25L/min. The recombinant BCL-2 was then passed over the bound Bax derivatives at 
5 serially diluted concentrations (1.56, 0.78, 0.39, 0.195, and 0.0975 mg/ml) at a flow 
rate of 25L/min.  Kinetic information was calculated using the Scrubber2 program 
(BioLogic Software). 
Statistics. 
Statistical analysis and experimental significance was determined using Prism5 
for Windows, Version 5.02 (GraphPad). 
Results 
Mitochondrial Bioenergetics Requires Bax.   
To determine whether Bax has a previously unrecognized non-apoptotic activity, 
we examined mitochondrial structure, function and bioenergetics in Bax +/+ and Bax -/- 
HCT-116 colon cancer cells.  MitoTracker Red 580 fluorescence intensity was used as 
an indicator of oxidative capacity and to visualize actively respiring mitochondria [68].  
Live-cell imaging was performed to ensure that fixatives would not disrupt MitoTracker 
uptake.  In Figure 8A, when Bax is present, we observed respiring mitochondria that 
appeared elongated and tubular in shape with a loosely dispersed branching network 
(Figure 8A).  In contrast, when imaging of the Bax -/- cells, we observed that, in the 
absence of Bax, respiring mitochondria were numerous but appeared less elongated 
(Figure 8B).  These observed differences in functional morphology upon MitoTracker 
staining were not due alterations in the fission/fusion process.  Treatment with Mdivi 1, a 
 
30 
chemical inhibitor of DRP1 that prevents fission by blocking the early stages of DRP1 
assembly, resulted in uniform changes in MitoTracker fluorescence that were 
independent of Bax’s presence in the cell (Figure 7). 
To determine whether loss of Bax changed mitochondrial density, accounting for 
the differences observed in MitoTracker staining (Figures 8A, 8B), we probed Bax +/+ 
and Bax -/- HCT-116 cells with N-nonyl acridine orange (NAO).  NAO accumulates in 
mitochondria by binding to negatively charged phospholipids, specifically, cardiolipin 
[69], [71].  Hence, NAO accumulation is not dependent on mitochondrial respiration and 
would directly show mitochondrial content.  Seen in Figures 8A and 8B, NAO 
incorporation in mitochondria was similar in both Bax +/+ and Bax -/- HCT-116 cells. This 
was confirmed by the measurement of total NAO fluorescence in each cell population 
(Histogram, Fig. 8C).  Hence, total mitochondrial density or content was independent of 
Bax expression.  To confirm results from NAO staining, we performed a quantitative 
experiment, measuring total mitochondrial DNA (mtDNA) relative to nuclear DNA 
(nDNA).  These results are shown in Table 2. We found no detectable differences in 
mtDNA content between Bax +/+ and Bax -/- HCT-116 cells, with -p values that were not 
significant.  In total these results suggest that the observed morphological differences 
detected by MitoTracker staining (Figure 8) were due more to a functional defect rather 
than decreased mitochondrial content.  To demonstrate that Bax +/+ and Bax -/- HCT-116 
cells were equally viable, we stained cells with NAO and ethidium bromide (EB). EB 
stains DNA only when the cell membrane is ruptured, as it is in apoptotic cells in culture.  
Representative data displayed in Figure 8D revealed no significant Bax -dependent 
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differences in overall viability. Approximately only 2-4% of the Bax +/+ and Bax -/- HCT-
116 cells were found to be apoptotic, or double-stained for both NAO and EB, and about 
30% of the cells were viable (negative EB staining) but had low NAO fluorescence that 
was unrelated to Bax expression. The viability of cell lines used in all experiments 
reported herein was consistent with the data shown in Figure 8D. 
To explore a possible functional defect upon Bax loss that was revealed by 
MitoTracker staining, we examined the electrochemical properties of the mitochondria in 
the two HCT-116 Bax variants using the uncoupling agent, FCCP.  FCCP is a 
hydrophobic compound that carries protons across the inner mitochondrial membrane 
(IMM), releasing these protons into the matrix and allowing for the dissipation of the 
chemiosmotic gradient.  A titration of FCCP was previously performed to determine the 
optimal concentration of FCCP for use, that is, caused the least effect on cell viability 
and the most effect on ATP production (data not shown).  When treated with FCCP, Bax 
+/+
 mitochondria displayed a stronger intensity of MitoTracker fluorescence compared to 
untreated cells (Figure 9A, 9C).  This was not observed in Bax -/- cells (Figure 9B, 9C). 
Although relaxation of MitoTracker fluorescence quenching has been reported with 
FCCP, we do not think this artifact is the reason for the observation made with Bax +/+ 
cells, since the increase in MitoTracker fluorescence was not also observed in Bax -/- 
cells.  Quantification of the effect of FCCP treatment revealed a two fold increase in 
MitoTracker fluorescence in Bax +/+ cells compared to untreated cells that was not 
observed with Bax -/- cells (Figure 9C).  We propose that, in Bax +/+ cells, the FCCP-
mediated uncoupling of the electron transport system results in the rapid oxidation of 
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matrix substrates, such as MitoTracker Red 580, which can be detected as an increase 
in MitoTracker fluorescence [69].  This does not occur in Bax -/- cells, suggesting that 
loss of Bax may result in a defect in mitochondrial oxidative capacity. 
Bax -/-cells also had significantly decreased levels of intracellular ATP as 
compared to Bax +/+ cells (Figure 9D).  Furthermore, FCCP treatment resulted in a 
marked drop in ATP levels in Bax +/+ cells, but not in Bax -/- cells (Figure 9D).  Note that a 
previous titration of FCCP concentrations correlated with ATP amounts detected, 
indicating that we were primarily assessing changes in ATP production (data not 
shown). To determine whether the loss of ATP in Bax -/- cells was due to abnormal 
bioenergetics, we measured glycolysis and oxygen consumption using an XF analyzer.  
Metabolic activity in Bax +/+ and Bax -/- HCT-116 cells was assessed by plotting the 
oxygen consumption rate (OCR), a measure of mitochondrial respiration, against the 
extracellular acidification rate (ECAR), an indicator of glycolysis.  Comparing changes 
that occur in aerobic and glycolytic metabolism, in Figure 9E, revealed that Bax +/+ cells 
had increased oxygen consumption (OCR) and decreased glycolytic activity (ECAR) 
relative to Bax -/-cells; hence Bax -/- cells were more dependent on glycolysis for their 
energetic needs.  A separate measure of oxygen consumption, using an alternative 
method, confirmed these findings (Figure 9F).  In support, we had previously observed 
that Bax -/- cells were more susceptible to glucose deprivation, acquiring a shrunken 
morphology with decreased cytosolic content as compared to Bax +/+ cells (Figure 10).  
From our experimental findings, we concluded that the decreased levels of ATP 
observed in Bax -/- cells was likely due to depressed respiration, indicating that cells 
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lacking Bax had a significant defect in oxidative phosphorylation that was in part 
compensated by glycolytic energy production. 
Bax Contributes to ATP production. 
Having identified a non-apoptotic function for Bax in the regulation of 
mitochondrial metabolism, we determined whether Bax could localize to the 
mitochondria in the absence of induced apoptosis.  We performed an 
immunofluorescence experiment, using Bax +/+ HCT-116 cells, and were able to detect 
partial co-localization of Bax with mitochondria (HSP-60 used as a mitochondrial 
marker) (Figure 11A).  To better quantitate the interaction of Bax with mitochondria 
under standard growth conditions, ultra centrifugation of enriched mitochondria was 
performed to examine the localization of Bax.  Note that lysates were prepared from 
cells that were viable (Figure 8D), and the isolation procedure ensured that only intact 
mitochondria were used.  The enriched mitochondrial lysate was layered on an iodixanol 
gradient and subjected to ultracentrifugation as described in Methods.  Separation of 
organelles was based on density, which is defined as a function of the protein-lipid ratio 
of the organelle membranes.  Western blot analysis of the gradient fractions for 
Prohibitin (mitochondrial content) (Figure 11B) showed that the distribution of the 
mitochondria between Bax +/+ and Bax -/- HCT-116 cells was comparable (across the 20-
23% fractions).  While no Bax was detected in Bax -/- cells, approximately 7% of the total 
endogenous Bax detected in the non-apoptotic Bax +/+ cells was associated with the 
mitochondrial fractions (Figure 11B, Table 3).  Using the appropriate loading controls, 
the percentage of Bax localized to the mitochondria was determined by densitometry, 
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calculating the relative band intensity in each lane compared to the amount of Bax 
detected in a5 western blot of whole cell lysates (data not shown).  This finding 
suggested that the amount of mitochondria-associated Bax that supports energy 
production is considerably less than the amount that is required for the Bax mediated 
perpetuation of the apoptotic cascade. 
It remained to be determined whether Bax was loosely associated with 
mitochondria (i.e. bound to the outer mitochondrial membrane (OMM)) or whether it was 
sequestered within an inner membrane compartment (i.e. IMM).  Enriched mitochondrial 
lysates, as those used for the ultracentrifugation experiment, were treated with 
Proteinase K for as few as 5 and up to 20 minutes.  Digested lysates were analyzed by 
SDS-PAGE and immunoblotted with antibodies to detect Bax, and, as a control, BCLXL.  
BCL-XL is mainly an OMM localized protein and is sensitive to protease digestion.  We 
found that treatment with Proteinase K resulted in 50-60% lysis of Bax, compared to 
BCLXL, in which 77-100% of the protein was lysed (Figure 11C). Although in the same 
sample there was less BCLXL protein detected compared to Bax, an increase in the 
amount of BCLXL digested occurred over time, while Bax was mostly digested within the 
first 5 minutes.  These results suggest that a significant amount of Bax was sequestered 
within the mitochondria and not accessible to protease treatment.  Hence, Bax has both 
outer and inner mitochondrial localization, supporting its proposed role mediating 
mitochondrial respiration.  The argument that Bax could be directly regulating 
mitochondrial metabolism was further demonstrated by measurements of citrate 
synthase activity.  Citrate synthase, which is localized to the mitochondrial matrix, is one 
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of the primary enzymes of the TCA cycle. We found that Bax -/-cells had reduced levels 
of citrate synthase activity in comparison to Bax +/+ cells (Figure 11D).  It is important to 
note that background levels of citrate synthase released from ruptured mitochondria 
were not significantly different in the Bax variants (Figure 11D). 
To confirm that loss of Bax is sufficient to inhibit ATP production, and is not due 
to a defect inherent to Bax -/- cells, Bax +/+ HCT-116 cells were treated with SMARTPool 
Bax siRNA.  Previously, using Cy3-tagged non-specific control siRNA, we established 
uptake efficiency and the absence of non-target effects in HCT-116 cells (data not 
shown).  After Bax siRNA treatment, cells were lysed and protein lysates analyzed by 
western blot for inhibition of Bax expression and measured for ATP production.  Bax 
protein expression was reduced approximately 50% when treated with Bax siRNA, as 
shown in a representative blot (Figure 12A).  This correlated to a reduction in ATP as 
well, indicating that the amount of available Bax dictated the effect on the ATP produced 
(Figure 12B).  We repeated this experiment using a lung cancer epithelial line, which is 
highly dependent on oxidative phosphorylation, to ensure that this phenomenon was not 
isolated to HCT-116 cells.  Western blot and ATP analysis of these lung cancer cells 
showed that a reduction in Bax expression correlated with the measured decrease in 
ATP levels (Figures. 12A, B). 
The work presented indicated that cell lines lacking Bax had reduced ATP 
production due to depressed respiration.  To show that these results were not due to 
cell line or culture artifacts, we examined mitochondrial metabolism in primary 
hepatocytes freshly isolated from Bax KO mice.  We observed that livers from Bax KO 
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mice were slightly enlarged compared to aged WT mice. Staining liver sections from 
Bax KO and WT mice with MitoTracker and NAO revealed findings very similar to those 
observed with HCT-116 cells (in Figure 8).  MitoTracker fluorescence was dim in liver 
sections from Bax KO mice as compared to WT mice, while NAO staining was 
comparable (Figure 13A, 13B).  Hence there appeared to be diminished mitochondrial 
respiration in Bax KO liver cells.  This was confirmed by measuring oxygen consumption 
of Bax KO hepatocytes compared to WT hepatocytes (Figure 13C).  ATP production 
was likewise reduced in Bax KO hepatocytes (Figure 13D) as well as citrate synthase 
activity (Figure 13E).  While, due to the limitations of cell numbers, biochemical assay 
results were less striking using freshly isolated hepatocytes, the differences between 
Bax KO and WT cells are statistically significant and follow similar patterns as those 
demonstrated with HCT-116 cells. 
Having found that inhibition of Bax replicated the loss of respiration seen in cells 
that were genetically ablated (Figures. 12 and 13); we next determined whether 
restoring Bax to deficient cells would rescue mitochondrial metabolic activity.  Over-
expression of full-length Bax (Bax -FL) in Bax -/- cells resulted in recovery of respiring 
mitochondria morphology (as seen in Bax +/+ cells in Figure 8A) observed upon 
MitoTracker staining (Figure 14A).  Western blot analysis of density gradients showed 
that ~2.5% of the total expressed protein associated with mitochondrial fractions (Table 
3, Figure 14B).  As a result, we observed a three-fold increase in ATP production upon 
the expression of Bax -FL that was inhibited by treatment with FCCP (Figure 14E).  This 
indicated that Bax -FL could rescue ATP production through oxidative phosphorylation.  
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ECAR/OCR measurements confirmed that expression of Bax -FL could increase 
oxygen consumption, while reducing glycolytic activity, indicating that Bax was a critical 
regulator of these activities (Figure 14F).  
Over-expression of C-terminal truncated Bax (Bax -CT) in Bax -/- cells was 
performed to determine the contribution of the C-terminal helix of Bax to mitochondrial 
bioenergetics.  Expression of Bax -CT did not restore the respiring mitochondrial 
morphology seen in the presence of Bax (Figure 14C).  This activity of Bax appears to 
require the C-terminal domain.  Predictably, the removal of this C-terminal helix resulted 
in a scattered localization of Bax -CT, as exhibited by the altered banding pattern in 
the gradient fractions (Figure 14D).  Even though mitochondrial targeting was 
deregulated in this mutant, some Bax -CT was found in the mitochondrial fractions 
(~9%, Table 3, Figure 14D), and, surprisingly, was sufficient to restore ATP production 
as effectively as Bax -FL (Figure 14E).  Moreover, measurements ECAR/OCR showed 
that expression of Bax -ΔCT was just as effective in restoring metabolic balance in Bax -
/-
 cells as Bax -FL (Figure 14F). The differences between Bax -/-cells and Bax -/- cells 
expressing Bax -FL or Bax -ΔCT were statistically significant. There results suggest that 
there are multiple regulatory domains of Bax, such as the C-terminal helix or the BH3 
domain, which can operate independently of each other to affect the function of 
mitochondria. 
Interaction with BCL-2 Blocks Bax’s Non-Apoptotic Activity. 
Bax’s known antagonist is the anti-apoptotic protein,  BCL-2, which resides 
anchored in the outer mitochondrial membrane [72].  Bax and BCL-2 exist in a balance 
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– each countering the other’s activity [73].  This balance is likely dependent on 
interactions mediated through each of the proteins' BH3 domains [74].  Since 
expression of Bax -ΔCT could rescue mitochondrial respiration and ATP synthesis, we 
postulated that this activity was being mediated through Bax’s BH3 domain, which could 
be inhibited by binding to BCL-2.  To test this, the binding capabilities of the Bax 
constructs with BCL-2 were first measured by SPR.  Recombinant Bax -FL or Bax -CT 
proteins were generated and covalently linked by amine coupling to gold SPR sensor 
plates. The recombinant BCL-2 protein was then passed over the bound Bax constructs.  
Binding kinetics was determined by calculating the association constant (ka) and 
dissociation constant (kd) of serially diluted BCL-2 binding to immobilized Bax.  The 
binding profile of BCL-2 to both Bax proteins was similar, but based on the kinetics, 
BCL-2 bound with twice the affinity to Bax -CT when compared to Bax -FL (Figures. 15 
A, B).  This disparity in binding affinities was exemplified by the two fold difference in the 
calculated equilibrium constant (KD) between Bax -FL and Bax -CT. This outcome is 
likely due to a greater exposure of a BCL-2 interacting domain in Bax -CT resulting 
from removal of the C-terminus of the Bax protein. 
Over-expression of BCL-2 in Bax +/+ cells resulted in decreased mitochondrial 
ATP production (Figure 15 C), indicating that BCL-2 was impeding the normal function 
of Bax in mitochondria.  This reduction was equivalent to the reduction observed upon 
FCCP treatment of Bax +/+ cells.  Adding FCCP to the BCL-2 over-expressed cells 
further amplified the reduction of ATP (Figure 15 C).  Because of the effects of binding 
to BCL-2 that are observed in both the Bax -FL and Bax -CT mutant (Figures. 15 A, B), 
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it can be inferred that BCL-2 also acts as an antagonist to Bax’s activity in promoting 
bioenergetics.  Since Bax still binds BCL-2 in the absence of the C-terminus, it is 
possible that a regulatory region, likely the BH3 domain, for this interaction becomes 
more accessible upon deletion of the C-terminal helix, and that this domain could 
associate with other mitochondrial membrane proteins to support ATP synthesis. 
 
Discussion 
 Our findings suggest that Bax has an essential, non-apoptotic, 
homeostatic activity.  Although the major portion of Bax in non-apoptotic cells resides in 
a soluble, cytosolic form [10], we and others [75] have observed that under normal 
conditions, Bax can also associate with mitochondria.  Herein, we report that Bax has a 
supporting role in mitochondrial energy production.  Cells deficient in Bax had 
decreased mitochondrial oxidative capacity and reduced levels of intracellular ATP.  
Such cells were dependent on energy produced through glycolytic activity. The 
localization of a small fraction of Bax to outer and inner mitochondrial compartments 
could enable ATP production through respiration, a process reversed when Bax was 
inhibited by specific siRNAs or genetically ablated such as in knockout mice.  By 
introducing Bax -FL into cells lacking endogenous Bax, we were able to restore 
mitochondrial respiration and increase the amount of ATP.  Expression of a Bax mutant 
lacking the C-terminal 9 helix also restored aerobic metabolism and ATP production, 
indicating that Bax was required for mitochondrial bioenergetics in manner that is 
independent of the C-terminal trans-membrane helix.  Co-expression of Bax with BCL-2 
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resulted in reduced ATP detection, suggesting perhaps that the interaction of Bax with a 
mitochondrial protein(s) (inhibited by BCL-2) was required for regulation of ATP levels. 
In the current model of apoptosis, the cytosolic, monomeric (inactive) form of Bax 
must undergo significant conformational changes (activation), which enable transitioning 
to mitochondria [3].  We may infer from our results that, under non-apoptotic conditions, 
equilibrium could exist between the two conformations, inactive and active.  A small 
amount of “active” Bax could associate with healthy mitochondria, contributing to the 
regulation of functional architecture and bioenergetics, but at a concentration well under 
that needed to induce apoptosis. This leads to the idea that the movement of Bax to 
mitochondria under non-lethal conditions could be restricted by the lipid and protein 
composition of the organelle membrane [76], [77].  Apoptosis induces changes in 
mitochondria that could help recruit Bax, while, in the absence of apoptosis the outer 
mitochondrial membrane environment is less likely to support the translocation of Bax.  
In healthy mitochondria, a few Bax monomers or dimers may insert into mitochondrial 
membranes to form small pores, but this process needs to be tightly regulated.  It is 
more feasible that Bax interacts with existing mitochondrial proteins.  This idea is 
supported by our findings that a portion of Bax was sequestered within the 
mitochondria, perhaps interacting with an IMM protein.  Hence, the amount of Bax 
associated with mitochondria in non-apoptotic cells would be constrained by the 
availability of the binding partner(s), a process we demonstrated by the inhibition of ATP 
production with co-expression of a known inhibitor (BCL-2) with the Bax constructs. 
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A review of current literature reveals a number of possible mitochondrial binding 
partners for Bax, although most were discovered in the context of an apoptotic scenario.  
Examples include the adenine nucleotide translocator (ANT) [78] and the voltage-
dependent anion channel (VDAC).  VDAC could serve as a mitochondrial receptor for 
Bax [79].  In addition to ANT and VDAC, many other proteins are known to interact with 
Bax, including factors that mediate changes in the mitochondrial network such as fission 
or fusion proteins like Drp1 [80], Mfn-2 [81] or endophilin B1 (Bif-1) [82] as well as other 
regulatory proteins such as cyclophilin D or Ku70 (reviewed in [83]).  Although this may 
seem speculative, the excess of circumstantial evidence for the interaction of Bax with 
healthy mitochondria highlights the need for further study to determine whether some of 
these proteins act to facilitate Bax’s role in mitochondrial bioenergetics. 
In a recent proteome-wide quantification of proteins that are differentially 
expressed between Bax -containing and Bax -deficient HCT-116 cells [84], a number of 
mitochondrial proteins were found to be down regulated upon loss of Bax, including 
VDAC.  Significantly, two essential enzymes for glucose metabolism and ATP 
production were also decreased in Bax -deficient cells: Glucose-6-phosphate isomerase 
was reduced over 10-fold and citrate synthase was reduced over 7 -fold.  This supports 
our own observation of reduced citrate synthase activity in the absence of Bax.  Loss of 
critical metabolic components exacerbates the inability of Bax -deficient cells to produce 
energy from glucose.  That the reintroduction of Bax into these cells dramatically 
increased respiration and ATP production, as we showed, strongly supports the concept 
that Bax plays an important homeostatic role supporting growth and metabolism.  Given 
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the decisive role of Bax in apoptosis, it would seem that the mutation rate in cancerous 
cells would be equivalent to p53, yet this is not observed.  There are only a handful of 
documented cases in which there is a complete mutational inactivation (or deletion) of 
Bax, one of which is in colorectal cancer [85]. More commonly, only mutations that 
restrict the pro-apoptotic activity of Bax are seen [64]. However, the nature of cancerous 
cells is one of perpetual proliferation at high energy costs, thereby demanding a 
constant generation of ATP.  Cancerous cells are known to generate their energy 
through glycolysis rather than oxidative phosphorylation – a phenomenon known as the 
Warburg effect [86].  It is possible that a partial deletion of Bax, or over expression of 
BCL-2 as occurs in many cancers, would favor the glycolytic pathway. This indicates 
that, perhaps due to its non-apoptotic function in maintaining energy production, the 
total inactivation of Bax in cancer would be rare, while retention of partial activity would 
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.  Level of mtDNA content in  Bax +/+ and  Bax -/- HCT116 cells 
 
HCT 116  Bax +/+ HCT116  Bax -/- P Value 
∆Ct -0.355 -0.318 0.4044 
2∆Ct 0.782 0.802 0.4047 
mtDNA/nDNA r = 0.644 r = 0.681 0.1967 
P values were determined using Unpaired t test with Welch's correction 


















 Association of Membrane-bound  Bax  with Different Density 














Bax  (+/+) 7.21 
 
47 53 
Bax  (-/-) 0  0 0 
Full Length 2.73  0.9 91 
CT  9.46  67 33 
*Data shown was determined by quantification of the mean pixel intensity of the 
BAX and prohibitin bands from blots shown Figures 3B, and 5B, 5D, and are 









Figure 7: Treatment with the fusion inhibitor, Mdivi-1, did not alter MitoTracker staining.   
Bax
 +/+
 HCT 116 cells (A) and Bax
 -/-
 HCT 116 cells (B) MitoTracker incorporation allows for qualitative 
analysis of the shape, distribution and oxidative capacity of the mitochondria.  Inhibition of fission 
machinery by Mdivi-1 was followed by incorporation of MitoTracker. Bax
 +/+
 (C) and Bax
 -/-
 (D) HCT 116 
cells were treated with 5um Mdivi-1 for 2 hours prior to imaging.   
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Figure 8: Reduced metabolic activity in Bax deficient cells is not related to mitochondrial content 
or loss of viability.   
Bax
 +/+ 
HCT-116 cells (A) and Bax
 -/-
 HCT-116 cells (B) were cultured on MatTek 24-well glass bottom 
plates coated with laminin to 70-80% confluence.  The cells were treated with MitoTracker Red 580 or 
NAO prior to imaging as described in Methods.  Live cell images were obtained using the UltraView 
(PerkinElmer) spinning disc confocal system.  The stand was a Zeiss AxioObserver Z.1 with a Plan-
Apochromat 63x/1.4 Oil DIC objective with a resolution of 0.124m.  Post-acquisition processing was 
done using Velocity software (PerkinElmer).  Images are representative of three replicates per condition.  
Insets are 10X magnification of the two highlighted areas in each field.  (C, D) To assess mitochondrial 
density (C) and viability (D), 500,000 cells/sample were stained with NAO (C) or NAO and ethidium 
bromide (EtBr) (D) for 10 minutes.  Fluorescence output was read using the FL1 and FL3 channels on a 
C6 flow cytometer (Accuri).  Each experiment was performed in triplicate for each cell line variant.  
Representative data are shown.  The data plotted in histogram and dot plots was analyzed using 







Figure 9: Deficiency of Bax results in reduced intracellular ATP and oxygen consumption.  
Bax
 +/+
 HCT-116 cells (A) and Bax
 -/-
 HCT-116 cells (B) were cultured on MatTek 24-well glass bottom 
plates coated with laminin to 70-80% confluence.  Cells were treated with FCCP in McCoy’s complete 
media for two hours prior to imaging.  Live cell images were obtained using the UltraView (PerkinElmer) 
spinning disc confocal system.  The stand was a Zeiss AxioObserver Z.1 with a Plan-Apochromat 63x/1.4 
Oil DIC objective with a resolution of 0.124m.  Insets are 10X magnification of the two highlighted areas 
in each field.  Post-acquisition processing was done using Velocity software (PerkinElmer).  Images are 
representative of three separate experiments with two replicates per condition.  (C) Calculation of 
MitoTracker fluorescence intensity was done with Velocity software by averaging the mean intensity of 
the voxels in each fluorescent cell.  (D) ATP concentration was assessed by measuring the activity of 
Luciferase as relative luminescence units (RLU).  (E) OCR and ECAR data obtained from the Seahorse 
XF24 Analyzer was calculated based on the oxygen consumption and acidification rates of 40,000 cells 
per well.  The values were pooled from three separate experiments and normalized to changes from the 




 cells was measured over time as a 
function of increased fluorescence.  Fluorescence, oxygen biosensor, and ATP data are representative of 
n=6.  The values for the ATP, OCR and ECAR assays were normalized to cell number per well, and 






Figure 10:  Cells deficient in Bax are susceptible to glucose deprivation. 
The effect of glucose withdrawal on Bax
 +/+
 HCT-116 cells (A) and Bax
 -/-
 HCT-116 cells (B) was 
determined by assessing cellular morphology using DIC imaging at 20x magnification, with the small 
scale used to acquire images in each field.  To deprive glucose, cells were cultured in complete RPMI 
media without D-Glucose (GFM) for 24 hours. The effects of glucose re-addition were assessed after 










 HCT-116 cells were fixed and stained with the indicated fluorochrome-conjugated antibody as 
described in Methods.  Confocal microscopy of cells shows endogenous Bax, in green, the mitochondrial 
protein, HSP60, in red, and in the merged field, yellow regions indicate co-localization of Bax with HSP60.  
Images were acquired with LSM 510 using 100x/1.4 Oil DIC objective and are representative of ten 
different images scanned from three separate experiments.  (B) Enriched mitochondrial lysates of 




 HCT-116 cells and subject to differential 
ultracentrifugation as described in Methods.  Gradient fractions collected were analyzed by SDS-PAGE 
and membranes immunoblotted for the presence of Bax, Prohibitin (mitochondria), and GRP78 (ER).  
Each blot shown is representative of three independent experiments.  (C) Western blot analysis of 
mitochondria isolated from Bax
 +/+ 
cells shows the effects of Proteinase K digestion on mitochondrial 
membrane proteins over time.  The extent of the digestion was calculated based on the percent change in 
densitometry between the treated and untreated samples.  (D) The assessment of citrate synthase 
activity was determined by the rate of formation of thionitrobenzoic acid (TNB) as described in Methods.  
The rate of activity is shown as μMol/ml/min.  Background levels of citrate synthase activity in 
spontaneously ruptured mitochondria are included as controls.  The data encompasses two separate 









+/+ HCT-116 or lung cancer cells (LC) were seeded at a density of 200,000 cells/well in 6-well plates.  
After 24 hours, Bax SMARTpool siRNA (Dharmacon) or non-targeting siRNA was delivered using the 
Accell reagent (Dharmacon). Cells were analyzed 72 hours later.  Controls cells received the Accell 
reagent alone.  No significant differences were previously observed between Accell reagent alone and 
Accell reagent with non-targeting siRNA.  (A) Cells treated with Accell reagent alone or Accell reagent 
with Bax siRNA were lysed for western blot analysis of Bax.  Densitometry readings, indicative of fold 
changes in Bax expression, are shown. Images are representative of triplicate experiments.  Calculations 
are based on multiple samples (n=4).  Samples were normalized to cells without Bax siRNA.  (B) For ATP 
assay, cells were counted and plated at a density of 4000 cells/well.  Treatments included Accell reagent 
alone and Accell reagent with non-targeting siRNA (NTsiRNA) or Bax siRNA (siRNA). ATP assays were 







Figure 13: Liver hepatocytes from Bax deficient mice have with reduced metabolic activity, 
resulting in decrease ATP and oxygen consumption. 
Sections of the caudate lobe of the liver (A) from Bax KO and C57BL6 mice were stained with 
MitoTracker Red or NAO.  (B) Isolated hepatocytes from these mice were stained with NAO and 
measured by flow cytometry to determine mitochondrial content.  Data is representative of 3 replicates 
and n=2 for each group.  (C) Oxygen consumption of 50,000 isolated hepatocytes per well was measured 
over 24 hours.  The data is representative of two experiments each with 46 replicates per group.  (D) ATP 
content was measured in isolated hepatocytes.  Luminescence was normalized to 5,000 cells per well 
and each of three experiments consisted of 42 replicates per condition.  (E) Citrate synthase activity was 
examined in isolated mitochondria by measuring the absorbance of TNB over time.  ATP and citrate 





Figure 14 : Expression of full Length Bax restores mitochondrial association and ATP production 
in Bax deficient cells. 
Bax
 -/- 
 HCT-116 cells were transfected with a ProteoTuner bi-cistronic vector expressing either Full 
Length (FL) BAX (A, B) or BAX-CT(C, D) and GFP.  (A, C) Cells were grown on MatTek plates as 
described in Methods, and transiently transfected (efficiency 60-70%).  Shield was added to induce 
expression.  Transfected cells were imaged based on GFP expression, and MitoTracker Red was used 
for mitochondria visualization.  Live cell images were obtained using the UltraView (PerkinElmer) spinning 
disc confocal system.  The stand was a Zeiss AxioObserver Z.1 with a Plan-Apochromat 63x/1.4 Oil DIC 
t 10X magnification.  Post-acquisition 
processing was done using Velocity software (PerkinElmer).  (B, D) BAX
-/-
 HCT-116 cells were 
transfected with either BAX-FL or BAXCT as described above.  Mitochondrial enriched lysates were 
subjected to differential ultracentrifugation and SDS-PAGE as described in Methods.  Membranes were 
probed with antibodies for BAX, prohibitin (mitochondria) and GRP78 (ER).  Images are representative of 




 HCT-116 cells, and BAX
-/-
 HCT-116 
cells transiently transfected with BAX-FL or BAXCT (C) were treated with and without FCCP and 
analyzed for changes in ATP levels as described in Methods.  (F) BAX
+/+





 HCT-116 cells, transiently transfected with BAX-FL (FL) or BAX-CT (CT or DCT,) 
were analyzed for changes in OCR and ECAR as in Methods.  One-way ANOVA was used for statistical 
analysis.  Microscopy and ATP data is representative of two experiments each with three replicates.  
OCR and ECAR data are representative of two experiments with a total of six replicates.  Statistical 
results for OCR and ECAR assays are p<0.05 (*) for BAX
-/-
 vs. BAX-FL and BAX
-/-
 vs. BAX-CT.  For the 





Figure 15: The interaction of Bax with BCL-2 inhibits the production of ATP in non-apoptotic cells 
SPR analysis of the binding of full-length Bax
 
-FL (A) or Bax
 
-CT (B) recombinant proteins with BCL-2 
was done by amine-coupling Bax to the sensor chip and then flowing BCL-2 over the immobilized Bax 
proteins.  Response is measured in micro-Refractive Index Units (RIU), and the equilibrium constants 
(KD) for each Bax construct were calculated from the observed association and dissociation constants (ka 
and kd) (Table).  (C) Bax 
+/+
 HCT-116 cells, Bax
 -/-
 HCT-116 cells, and Bax
 -/-





CT (for 18 hours) were treated with and without FCCP and analyzed for 





CHAPTER 3:  EXPLOITING THE INHERENT CYTOTOXICITY OF THE 
ALPHA-9 HELIX OF BAX FOR USE AS A PEPTIDE DRUG FOR 
CANCER THERAPY 
Introduction 
It is generally recognized that cell death can occur through diverse mechanisms, 
including apoptosis, programmed necrosis, autophagy or mitotic catastrophe. Most 
studied is the apoptotic pathway that is triggered by extracellular and intracellular cues 
and is governed by the relative ratios of pro- (i.e.: Bad, Bax, Bim, Bak) to anti-apoptotic 
(i.e.: Bcl-2, Bcl-XL) members of the Bcl-2 family of proteins.  Tumors expressing high 
levels of anti-apoptotic proteins, such as Bcl-2, Mcl-1 or Bcl-xl, are often resistant to the 
effects of chemotherapeutics [39]. This is accomplished, in part, by inhibition of the pro-
apoptotic Bcl-2 family members, such as Bax, first identified as a protein that interacts 
with  Bcl-2 [73]. A third group of Bcl-2 proteins, identified as the BH3-only proteins such 
Bid, Bim or Bad, tip the balance between anti- and pro-apoptotic members and serve as 
molecular tie breakers favoring cell death [87]. Comparably, less is known about the 
mechanisms that activate programmed necrosis, autophagy and mitotic catastrophe; 
however the Bcl-2 family members may play a role in these processes [88].  
To kill cancer cells, conventional chemotherapeutic agents typically rely on an 
intact apoptotic signaling pathway induced by cellular insults like ionizing radiation (IR), 
ultraviolet (UV) radiation, or reactive oxygen species (ROS) that can cause DNA 
damage. Resistance to chemotherapeutic agents may result from mutation, duplication, 
or elimination of gene products that are involved in the initiation and/or execution 
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apoptosis. As an example, DNA alkylating agents become ineffective in tumor cells in 
which p53 is mutated, resulting in transcriptional loss of Bad and Bax and impairment of 
the apoptotic program [89]. Due to the prevalence of tumors harboring p53 mutations, 
recent efforts have focused on directly targeting Bcl-2 family members. Whether acting 
directly or indirectly on the Bcl-2 proteins, most chemotherapeutic agents cause 
cytochrome C to be released from mitochondria leading to activation of effector 
caspases [90].  Thus, given the central role that mitochondria play in life and death, this 
organelle is a logical target for direct intervention with small molecules or peptides.  
Small molecules are easy to synthesize and have long half-lives.  However, in 
vivo efficacy is hard to predict given their extra-physiologic structures that could produce 
off target effects [91]. As a result, a number of small molecule cancer therapeutic agents 
have exhibited significant toxicity when translated for human use [92].  Several small 
molecule BH3 mimetics, including ABT-737 and navitoclax, are currently being 
investigated at varying levels of phases of pre-clinical and clinical trials[40], [93]. 
Despite their selective affinity for specific anti-apoptotic proteins, these compounds 
appear to be subject to the same constraints that affect other small molecule 
therapeutics: off-target cytotoxicity [38].  
As an alternative approach to the use of small molecules, anticancer peptide 
therapy focuses on the development of therapeutic peptides to kill cancer cells [94]. 
This approach has significant advantages over small molecules, including ease of 
design and synthesis.  A vast knowledgebase of normal protein function facilitates the 
intelligent design of peptides that can specifically target a protein of interest. This study 
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describes the rational development of a cytotoxic peptide that promotes non-apoptotic 
cell death. Guided by primary sequence similarities of the pro-apoptotic protein Bax to 
anti-microbial peptides and the evolutionary relationship of mitochondria to bacteria, we 
examined the suitability of a peptide modeled after the C-terminus of Bax (CT20p) as a 
selective mitochondrial pore forming therapeutic. Biophysical studies previously 
revealed that CT20p could form a pore that permits the passage of small molecules 
(Garg et al and Tatulian et al, submitted).  The purpose of the present study is to 
determine whether an inherent property of CT20p is the capacity to induce cell death 
that is non-apoptotic and could result in direct demise of cancer cells.  To introduce 
CT20p in vehicle that could be modified for tumor-targeting, the peptide was 
encapsulated in polymeric nanoparticles (NPs).  Polymeric NPs are inert particles that 
have the inherent capacity to incorporate drugs, dyes or tumor-targeting ligands, and, 
thereby, provide an ideal carrier for CT20p.  Data presented herein supports the 
development of CT20p-NPs as a novel cytotoxic that can be used alone or in 
combination therapies for the treatment of cancer. 
 
Materials and Methods 
Cell lines and CT20p. 
The Flp-In T-REx-293 cell line (Invitrogen) stably expresses the lacZ-Zeocin 
fusion gene and Tet repressor.  The 293 line was maintained in DMEM, 10% fetal 
bovine serum (FBS) (tetracycline-reduced), 2 mM L-glutamine and 1% Penicillin-




colorectal cancer cell lines [65] (gift from 
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Dr. Bert Vogelstein, John Hopkins University) were maintained in McCoy’s 5A media, 
10% FBS and 1% Penicillin-Streptomycin. The breast cancer cell lines, MCF-7 and 
MCB-MD-231 (ATCC), were maintained in DMEM, 10% FBS, and 1% Penicillin-
Streptomycin.  MCF-7 cells were supplemented with 1% L-Glutamine every 15 day. 
Early passages of all cell lines were frozen as stocks at time of receipt. Cell lines were 
used at less than 10 passages from stocks.  CT20p (Ac-VTIFVAGVLTASLTI WKKMG-
NH2) (Biopeptide Co., Inc.) was commercially synthesized at >98% purity. 
Plasmids, Mutagenesis and Transfection.  
For inducible expression of full-length Bax, we employed the Flp-In T-REx 
System (Invitrogen) following manufacturer’s protocol. Briefly, PCR-directed 
mutagenesis of K189/K190 was performed using HA-tagged primer sets. Bax constructs 
were amplified from pEGFP-Bax (gift from Dr. Richard Youle, NINDS, NIH), digested 
with EcoRV and cloned into the plasmid pcDNA5/ FRT/TO which undergoes DNA 
recombination at the Flp Recombination Target (FRT) site when co-expressed with the 
Flp recombinase pOG44 plasmid. Constructs were confirmed by sequencing; Fugene 
transfection reagent (Roche) was used to co-transfect plasmids at a ratio of 9:1.  Stable 
Flp-In T-REx expression cell lines were selected for Blasticidin resistance (10μg/ml), 
Hygromycin resistance (100μg/ml) and Zeocin sensitivity (200μg/ml).  Bax expression 
was induced with 1μg/ml tetracycline. Cells were assayed after 24 hours of induction. 
To generate the Destabilization Domain (DD)-tagged Bax C-terminal (CT) 
constructs (amino acids 173-192) with K189K190 (wild-type) or EE, LL, and RR 
mutations, primers were annealed and ligated into the ProteoTuner vector (Clontech) 
 
58 
digested by EcoRI and BamHI.  Generation of DD-tagged, full-length WT Bax was 
previously described [95].  The ProteoTuner IRES2 system (Clontech) also had the 
marker protein GFP downstream to the internal ribosome entry sequence (IRES) and 
was translated independently of the DD-tagged protein.  Cells were transiently 
transfected using the TransIT-LT1 transfection reagent (Mirus) for 24 hours and 
microscopically assayed for GFP expression. Expression of DD-tagged proteins was 
induced for 4-5 hours by adding 500nM of Shield (Clontech). 
MDA-MB-231 cells were transiently transfected with pcDNA-Bcl2 (gift from Dr. 
Wenqing Li, NCI-Frederick) (or as control pEGFP (Clontech)) using the TransIT-LT1 
transfection reagent (Mirus).  To assess transfection efficiency, cells assayed 
microscopically for EGFP expression. To assess Bcl-2 expression, cells lysates were 
immunoblotted as described below. 
Mitochondrial Translocation Assay and Immunoblotting. 
Mitochondrial and cytosolic proteins were isolated using a mitochondrial 
enrichment kit (Pierce).  Western blots were run using 12-15% SDS-PAGE gels and 
PVDF membranes and probed with the following primary antibodies: 16B12 anti-HA 
mouse monoclonal (Covance) for HA-tagged Bax; 631073 Anti-DD monoclonal 
(Clontech) for DD-Bax;  N-20 (Santa Cruz), for endogenous Bax, Ab-2 (Fitzgerald) for 
prohibitin, C20 (MAPK) (Santa Cruz) for p38 MAP kinase, and rabbit polyclonal for Bcl-2 
(Santa Cruz); this is followed by the appropriate secondary antibodies conjugated to 
horseradish peroxidase (HRP) and visualized with enhanced chemiluminescence kit 
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(Pierce). Molecular weight markers (SeeBlue Plus 2 (Invitrogen)) were used to 
approximate the position of protein bands in blots. 
Live-Cell Confocal Imaging. 
Images were acquired through a PerkinElmer UltraView spinning disc confocal 
system, with AxioObserver.Z1 stand (Carl Zeiss), in a humidity and temperature-
controlled chamber (LiveCell) with cells cultured on MatTek plates (MatTek 
Corporation). Post-acquisition snapshots were taken from time-lapse movies at time 
points indicated in the figures.  Time-lapse movies were initiated two hours after 
transfection or expression was induced and images acquired through 12 hours of 
expression using a Plan-Apochromat 10x objective. For DD-CT20 fusion proteins, cells 
were incubated with 1nM MitoTracker Red 580 for 30 minutes prior to imaging.  Time-
lapse movies were recorded for up to 12 hours using a Plan-Apochromat 63x Oil DIC 
objective.  
Visualization of the uptake and effects of the fluorescent dye (DiI)-loaded NPs 
(prepared as described below) in HCT-116, MCF-7 and MDA-MD-231 cells was 
observed  using a 10x air objective with a numerical aperture of 0.3, using ex/em of 
514/587.  All cells were loaded with MitoTracker as described above. Visualization of 
the HCT-116 cell lines was observed using Plan-Apochromat 63x Oil objective.  MCF-7 
and MDA-MB-231 images were captured using Plan-Apochromat 40x Oil objective.  All 
time-lapse images were generated in 2D by capturing 6 time points per hour for 24 
hours of the same field. 
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Treatments and Detection of Apoptotic Cells and Mitochondrial Membrane 
Potential by Flow Cytometry. 
HCT-116, MCF-7 or MDA-MB-231 cells were collected at a final concentration of 
1 x 106 cells/ml and assayed using the SYTOX® AADvanced™ dead cell stain solution 
(Invitrogen).  Cells were analyzed using the BD FACSCanto flow cytometer. SYTOX® 
AADvanced™ was visualized at 488nm and emissions collected at 695nm. Analysis of 
data was done using FSC Express software (DeNovo).  Membrane asymmetry was 
assessed using the Violet Ratiometric Membrane Asymmetry Probe/Dead Cell 
Apoptosis Kit (Invitrogen) according to the manufacturer’s protocol.  
The cell permeable dye, JC-1 (Molecular Probes), was used to qualitatively 
assess the mitochondrial membrane potential (). For detection, JC-1 was excited at 
488 nm and fluorescence measured at 530 (JC-1 monomers) and 590 (JC-1 
aggregates) nm.  JC-1 monomers accumulate in the cytosol while JC-1 aggregates 
accumulate in the mitochondrial matrix in a manner dependent on the mitochondrial 
membrane potential.  Briefly, MDA-MB-231 cells were seeded in 6 well plates and 
treated with CT20p or controls as described in Figure Legends.  JC-1 was used at 
5g/mL, and cells were incubated with the dye for 15 minutes in the dark prior to 
analysis.  Cells were analyzed by flow cytometry using the FACSCanto II (BD 
Biosciences).  Data was acquired in the FITC and PE channels for analysis.  FCS 
Express software (DeNovo) was used to analyze data. 
To study apoptosis, cells were pre-treated with 100µM of the pan-caspase 
inhibitor Z-VAD-fmk (EMD Biosciences) or transiently transfected with Bcl-2  (as 
described above), then treated with either CT20p-NPs (see below) or cisplatin (CDDP) 
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(gift from Dr. Deborah Altomare, UCF) alone or in combination as indicated in figure 
legends.  Following treatment, cells were analyzed as described above for cell death 
and membrane asymmetry.  
Synthesis of Polymeric NPs Encapsulating CT20p. 
CT20p was encapsulated into hyperbranched polymeric (HBPE) NPs following a 
previously reported method [96]. A fluorescent dye (DiI) was co-encapsulated with the 
peptide.  In brief, 1.0 µL of DiI dye (10 µg/µL) and 36 µL of CT20p (0.05 µg/µL) solution 
in 250 µL of DMSO were mixed in 250 µL of a DMSO solution containing the HBPE 
polymer (12 mg) for a ratio of ~ 0.15 g peptide: 1 mg nanoparticles. The resulting 
polymer-DiI/CT20p mixture in DMSO was added to deionized water (2.5 mL) to form the 
HBPE (CT20p/DiI) NPs. The resulting NPs were purified using a PD-10 column and 
dialyzed (MWCO 6-8K) against PBS (pH=7.4). Dynamic light scattering and zeta 
potential analysis of the nanoparticle reveals a size diameter of 88±2 nm and zeta 
potential of -54.5 mV. 
Synthesis of Aminated Polymeric NPs Encapsulating CT20p. 
The HBPE NPs (above) contain functional carboxylic groups on their surface that 
results in a negative charge. To introduce a positively charged surface the nanoparticles 
were aminated using  water-soluble carbodiimide chemistry [EDC: 1-ethyl-3-(3-
dimethylamino-propyl) carbodiimide hydrochloride and NHS: N-hydroxysuccinimide 
chemistry], following a previously reported method [96].  Briefly, to a solution of HBPE 
(CT20p/DiI) NPs (1.0 mmol) in PBS (pH = 7.4), a solution of EDC (10 mmol) and NHS 
(10 mmol) in MES buffer (pH = 6.0) was added.  Afterwards, ethylenediamine (10 mmol) 
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in DMSO was added to obtain aminated DiI/CT20p co-encapsulation polymeric NPs, 
which were purified and dialyzed as above. Dynamic light scattering and zeta potential 
analysis of the nanoparticle reveals a nanoparticle size diameter or 91±3 nm and zeta 
potential of + 10.3 mV.  All NPs were stored at 4C.  A final working concentration of 350 
pM was determined by testing the toxicity of 7, 1.4, 0.7 and 0.35 nM on HCT116+/+ cells. 
Calcein Release Experimental Protocol. 
Calcein release from artificial membranes was measured on a JASCO 810 
spectropolarimeter (Jasco Inc.) with a Peltier water cooled thermostat and a 
photomultiplier tube mounted at 90 degrees for fluorescence measurements. Large 
unilamellar vesicles (LUVs) were prepared with the following modifications: Lipids 
(Avanti Polar Lipids) in chloroform were mixed in the following molar ratios: 52.5% 1-
palmitoyl-2-oleyl-sn-glycero-3-phosphatidylcholine (POPC), 21% 1-palmitoyl-2-oleyl-sn-
glycero-3-phosphatidylethanolamine (POPE), 13% bovine liver L- phosphatidylinositol 
(PI), 10% cholesterol and 3.5% 1-palmitoyl-2-oleyl-sn-glycero-3-phosphatidylglycerol 
(POPG),  in order to mimic the outer mitochondrial membrane. After removing 
chloroform and desiccating, the dried lipid film was re-suspended in 50 mM HEPES, pH 
7, supplemented with 110 mM NaCl and 80 mM calcein and extruded with Avanti’s mini 
extruder (Alabaster, Alabama).  External calcein was removed by gel filtration through a 
1.5 x 50 cm Econo-Column (Bio-Rad) freshly packed with Sephadex 50 (GE 
Healthcare).  CT20p was added at concentrations equivalent to those used with cells in 
culture.  Calcein fluorescence was excited at 495nm and emission spectra recorded 
between 510 and 550 nm, (excitation/ emission slits: 10/ 3 nm).  Samples were 
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maintained at 37C and a final measurement taken at 24 hours. Maximum calcein 
release was obtained by the addition of Triton x100 (0.1% final concentration) to calcein 
loaded LUVs without nanoparticles that had been incubated at 37C for 24 hours after 
the addition of 10 l DMSO.  LUV integrity was monitored by light scattering at an 
excitation wavelength of 500 nm and detected at 90 degrees to the incident light. 
In Vivo Experiment. 
Two to five million MBA-MD-231 cells were harvested from culture and injected 
subcutaneously into the right flanks of 16 female nude mice (nu/nu, Charles River).  
After 2-3 weeks, tumor volume and growth was assessed by ultrasound (VisualSonics 
Vevo 2100).  Mice with tumors were injected intra-tumorally (IT) or intravenously (IV) 
with PBS, unloaded NPs, or CT20p-NPs at 4X the concentrations described above.  
Injections were performed once (IV) or twice (IT) over 4-15 day period.  Mice were 
observed 0-15 days post-treatments and tumor volume assessed by ultrasound. Given 
the size of the standard deviation and the difference in the means between groups of 
control and CT20p-NPs treated mice, at n=4 for each group, at 80% power the P values 
were less than 0.05.  This study was carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 





CT20p Enables Mitochondrial Membrane Binding and Permeabilization. 
The ability to selectively permeabilize membranes and kill cells is a feature of 
anti-microbial peptides (AMPs), whose fundamental structure involves clusters of 
hydrophobic and cationic residues (Table 4).  Most peptides with these sequences 
interact well with the negatively charged prokaryotic lipid membranes, but interact poorly 
with the more zwitterionic eukaryotic plasma membranes [97]. Mitochondria within 
eukaryotic cells resemble Gram negative bacteria in a number of ways: having a double 
membrane, circular DNA, and may have arisen through the process of 
endosymbiosis[98], [99]. Hence, AMPs introduced within eukaryotic cells could disrupt 
mitochondrial membranes, causing mammalian cell death.  As an example, a synthetic, 
anti-microbial-like peptide, D-(KLAKLAK)2, disrupts mitochondria and kills cancer cells 
when tagged with cell-penetrating peptides [100–102].  Based on this information, we 
sought to develop a new peptide with the features of AMPs that could be used to induce 
the selective death of cancer cells.  To this end, we examined different membrane-
binding domains from Bax, a death-inducing member of the Bcl-2 family. We found that 
the C-terminal 9 helix of Bax (basis for CT20p) contained clusters of hydrophobic and 
cationic residues (Table 4).  In fact, the arrangement of hydrophobic and cationic 
residues of CT20p was comparable to a number of AMPs, including those of the 
Brevinin family as well as Ranalexin.  CT20p also shared features with anti-microbial 
peptides, namely the double-lysines, not found in peptides composed of the 5-6 
helices of Bax or BH3 domain peptides (Table 4).  In fact, based on their sequences, 
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these latter peptides are likely to induce apoptosis by interacting with and blocking the 
activity of anti-apoptotic proteins rather than directly associating with mitochondrial 
membranes.   
To examine the capacity of CT20p to cause cell death by targeting mitochondria, 
we first examined the involvement of the double lysines in the context of the full-length 
Bax protein. Mutagenesis of the double lysines in the C-terminus of Bax was performed.  
Previously we found that constitutive expression of N-terminal-tagged Bax induced 
spontaneous cell death.  To avoid this, we inducibly expressed HA-tagged Bax in stably 
transfected Flp-In T-REx 293 cells. Bax constructs were integrated into the genome at a 
single FRT (recombination) site and the levels of Bax expression in these isogenic cell 
lines did not cause apoptosis. Localization of full-length, wild-type (WT) Bax (Bax-KK) 
was distributed among cytosolic and mitochondrial lysates (Figure 1A) as we and others 
have previously shown.  We found that N-terminal-deleted Bax (Bax-ΔNT) was localized 
primarily to mitochondria, while the C-terminal-deleted Bax, (Bax-ΔCT) was retained in 
the cytosol, indicating the importance of the N- and C-terminal domains in the 
localization of Bax (Figure 16A).  Substitution of the double lysines (K189/K190) with 
negatively charged residues, aspartic acid (D) or glutamic acid (E), resulted in the 
cytosolic retention of Bax (Bax-DD, Bax-EE) (Figure 16B).  Whereas substitution of the 
double lysines with positively charged arginine (R) (Bax-RR) led to mitochondrial 
localization (Figure 16B).  Substitution of the double lysines with a polar amino acid, 
glutamine (Q) (Bax-QQ), led to less mitochondrial Bax, when compared Bax-KK and 
Bax-RR (Figures. 16A, 16B).  Substitution of the double lysines with the hydrophobic 
 
66 
amino acid leucine (L) (Bax-LL) resulted in mitochondrial association, likely through 
increased hydrophobicity (Figure 16A).  Mutation of one lysine, K189, (Bax-EK) also 
rendered Bax cytosolic, which was not observed by mutation of K190 (Bax-KMGK) 
(Figures. 16A, 16B).  These results deleting or mutating the double lysines at the C-
terminus of Bax confirmed that these residues and the C-terminal helix were important 
for association of the full-length protein with mitochondria. 
Next, we determined whether CT20p retained the mitochondrial-binding 
properties of the full-length protein. To evaluate this, we fused only the CT20p domain 
to a short destabilization domain (DD) for detection and inducible expression.  CT20p 
fused to DD (DD-CT20) was inducibly expressed in HCT-116 cells.  Peptide localization 
was examined post-expression.  As control we compared DD-CT20 (KK and EE, LL and 
RR mutants) peptides to DD-tagged full-length (FL) Bax.  Previously we showed that 
induced expression of DD-FL Bax did not cause cell death in the absence of apoptotic 
stimuli [95].  Gene expression was induced for four hours after previous transfection of 
cells with DD-FL Bax or DD-CT20 peptide cDNA constructs.  Constitutive GFP 
expression from the bi-cistronic plasmid was controlled by an IRES element and used to 
detect transfected cells.  As shown in Figure 16B, most of DD-tagged FL Bax was found 
in cytosolic extracts, and a fraction of DD-FL-Bax was in mitochondria extracts.  The 
small 15-16 kD band of DD-CT20 peptides or DD-CT20 mutant peptides (EE, LL, and 
RR (fainter band)) was detected in mitochondrial extracts, indicating that the DD-CT20 
peptides were localizing to mitochondria. These results were confirmed by 
immunofluorescence (Data not shown). Expression of DD-CT20 also caused the 
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mitochondrial translocation of a small amount of endogenous Bax (Figure 16B).  
Additional experiments attaching CT20p to EGFP confirmed the findings that fusion of 
CT20p to a cytosolic protein could confer membrane binding properties.  It should be 
noted that in these experiments, detecting the localization of DD-CT20 or GFP-CT20 
proved challenging, even upon a short term of expression, because CT20 expression 
could cause significant cell death as shown in supplemental figures, indicating that its 
effects upon mitochondria had lethal consequences. 
To examine the effect that CT20p could have upon mitochondrial membranes, 
we directly evaluated its ability to disrupt lipid membranes and cause the release of 
sequestered contents.  LUVs composed of the phospholipids that make up the 
mitochondrial outer membrane were made as described in Materials and Methods and 
were loaded with calcein.  The release of calcein was measured by fluorescence 
spectrometry.  Controls were LUVs alone or LUVs treated with Triton X-100, which 
caused disruption of lipids and release of calcein.  The data in Figure 9A demonstrated 
that CT20p could insert into mitochondrial-like LUVs and cause the release of calcein 
(Figure 17A), without disrupting the integrity of the LUVs a shown by analysis of the light 
scattering pattern (Figure 17B).  A decrease in light scattering is evident when vesicle 
integrity is lost as seen in Triton X-100 sample (Figure 17B).  The extent of the light 
scattering was determined by the amount of light detected by the fluorescence detector.  
Because the detector is mounted at a 90 degree angle from the incident light, any signal 
detected at the incident wavelength (500 nm) is scattered light.  When the double 
lysines were mutated to leucines (CT20p-LL) or glutamic acids (CT20p-EE), minimal to 
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no release of calcein was detected and LUVs retained their integrity (Figures. 17A, 
17B).  In total these findings suggest that CT20p can insert into mitochondrial lipid 
membranes and permeabilize the membranes, perhaps by forming a pore-like structure. 
Delivery of the CT20p Using Polymeric NPs Kills Cancer Cells.   
Free peptides in aqueous solutions may not adopt the -helical conformation 
needed to penetrate cell membranes.  For this reason, modifications, such as chemical 
stapling [41], or the addition of membrane-penetrating sequences [103] have been tried 
by others to deliver free peptides to cells.  However, none of these methods can 
inherently target tumors.  To develop a robust delivery system for CT20p that could 
incorporate tumor-targeting ligands as well as conventional drugs, we turned to 
nanotechnology.  As CT20p is soluble in DMSO, it can easily be encapsulated within 
the hydrophobic pockets of aliphatic, polymeric NPs. A major advantage of such NPs is 
their ability to be modified with poly(ethylene glycol) (PEG), reducing non-specific 
interactions with proteins, increasing half-life and improving bio-distribution by 
increasing blood circulation time [104], [105].  Shown in Figure 11A is the scheme for 
generating the aliphatic, hyper-branched, polymeric NPs that contain DiI (fluorescent 
dye) and commercially synthesized CT20p.  Two forms of polymeric NPs were made: 
positively charged, aminated (AM) or negatively charged, carboxylated (COOH) 
nanoparticles [96].  To verify that the NPs would not release CT20p at neutral pH, 
calcein loaded liposomes were prepared. While CT20p alone (350 pM) resulted in the 
release of calcein from liposomes (as shown in Figure 2A), CT20p-NPs (350 pM) failed 
to do so, indicating that the peptide loaded NPs were intact at pH 7.  This confirmed that 
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cargo is released from NPs only within cells by intracellular esterases or acidic pH [96], 
indicating that polymeric NPs are a good vehicle in which to incorporate CT20p for 
delivery to tumor cells.   
Next we examined the uptake of DiI-loaded NPs and effect upon the viability of 
HCT-116 cells.  The representative experiment in Figure 18B showed that HCT-116 
cells take up NPs, uptake was better for the Bax-deficient cells compared to Bax-
containing cells, which could be due to their metabolic state since cells lacking Bax tend 
to be more glycolytic [95].  While the treatment of HCT-116 cells with unloaded NPs did 
not cause significant cell death (Figure 18B), treatment of HCT-116 cells with CT20p-
NPs (700 pM) resulted in observable morphological changes consistent with cell killing 
(Figure 18B).  As expected, treatment of cells with free peptide at doses equivalent to 
that available in the NPs, as well as 1000-fold greater, did not cause toxicity (data not 
shown).  To show that NPs alone did not cause death, we used a DNA-binding dye that 
detects membrane rupture of dead cells (Sytox).  In Figure 18C the results show that 
minimal (in Bax+/+ HCT-116 cells) to no (in Bax-/- HCT-116 cells) cell death was detected 
upon addition of DiI-loaded NPs (5g, 10g or 15 g) as compared to positive control 
(dead cells).  From this point on, to minimize off-target effects, all in vitro experiments 
were performed using approximately 350 pM CT20p-NPs. 
To visualize the effect of CT20p-NPs upon mitochondria, we stained Bax-
containing or Bax-deficient HCT-116 cells with MitoTracker and imaged live cells.  In 
Figure 19A and 19B are “snapshots” at 0, 12 and 24 hour time points revealing changes 
in cell morphology which include disruption of mitochondria (reduced or faint 
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MitoTracker staining), cell shrinkage and membrane perturbations, indicative of cell 
death.  Loss of membrane integrity was detected within three hours of treatment with 
CT20p-NPs (Figure 19C); more so for the Bax deficient cells that we had shown 
previously were more efficiently taking up NPs.  While both AM-NPs and COOH-NPs 
containing CT20p initiated cell death (Figure 19B-C), the COOH-NPs were more 
effective.  Further, these results with Bax-deficient cells indicated that the death-
inducing activity of CT20p was independent of endogenous Bax. 
Next, we determined whether CT20p was cytotoxic to the breast cancer cell 
lines, MCF-7 and MDA-MB-231.  In Figure 19A, we observed morphological changes 
such as diffused MitoTracker staining and cell shrinkage in MCF-7 cells treated with 
AM- or COOH-NPs containing CT20p, with COOH-NPs being the more effective.  Most 
MCF-7 cells died within 24 hours, while loss of membrane integrity was detected by 3 
hours of treatment (Figure 20B).  In Figure 19C, the live-cell imaging experiment 
revealed vacuolization and cell shrinkage of MDA-MB-231 cells treated with CT20p-
NPs.  Within three hours, increased membrane rupture was detected in MDA-MB-231 
cells treated with COOH-NPs loaded with CT20p (Figure 20D). Because the cytotoxic 
effect of the CT20p was more pronounced for the breast cancer cells (Figure 20) 
compared to HCT116 cells (especially the Bax-containing HCT116 cells (Figure 19), it 
remains possible that the CT20p-NP compound could be a potent inducer of death in 
metabolically active cells.  These results show that CT20p, once introduced into cells, 
can rapidly trigger cell death, detectable by pronounced morphological changes.  
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Because of these results, Subsequent experiments performed with done using COOH-
NPs to encapsulate CT20p. 
The Death-Inducing Activity of CT20p is Independent of Caspases and 
Resistant to Bcl-2, Causing Tumor Regression. 
To investigate whether the mechanism by which CT20p induced cell death 
involved apoptosis through the intrinsic mitochondrial pathway, we treated MDA-MB-
231 cells with CT20p-NPs as described in Figure 20, adding a caspase inhibitor or over 
expressing Bcl-2.  Cell death was measured by the uptake of Sytox, an indicator of 
membrane rupture.  As shown in the representative experiment in Figures 21A, CT20p-
NPs caused significant loss of membrane integrity, seen as an increase in Sytox 
staining, which was minimally impaired by caspase inhibition with Z-VAD-FMK.  In 
contrast, treatment of MDA-MB-231 cells with cisplatin (CDDP) induced less cell death 
detectable by Sytox but was inhibited over 50% by Z-VAD-FMK.  These results 
suggested that the mechanism induced by CT20p could be different than that induced 
by CDDP, and was largely independent of the effector caspases inhibited by Z-VAD-
FMK.  We next over expressed Bcl-2 and found that did not impair the death activity of 
CT20p.  Overexpression of Bcl-2 did, however, inhibit the effects of CDDP treatment 
(Figure 21A).  Combination of CDDP followed by treatment with CT20p-NPs proved to 
be the most effective in inducing cytotoxicity that was not inhibited by Z-VAD-FMK or 
Bcl-2 (Figure 21A).  We confirmed that transfected cells were expressing Bcl-2 by 
immunoblotting lysates prepared from cells.   
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While Sytox is good indicator of cell death, it only reveals whether membrane 
rupture has occurred.  To determine whether CT20p could induce apoptotic cell death, 
we measured membrane asymmetry caused by flipping of phospholipids in the plasma 
membrane using a violet ratiometric probe.  In Figure 21B, dot blots show the 
comparison of loss of membrane integrity to changes in membrane symmetry in MDA-
MB-231 cells treated with CT20p-NPs and/or CDDP.  We found that treatment with 
CT20p-NPs resulted in uptake of the DNA-binding dye (as shown in Figure 21A), 
indicating membrane disturbance, but did not promote changes in membrane 
asymmetry typical of apoptosis. Death induced by CT20p-NPs was slightly affected by 
caspase inhibition (39.5% reduced to 22% Sytox-positive) but did not approach 
untreated conditions (1.7% Sytox-positive).  Over expression of Bcl-2 did not block the 
death-inducing activity of CT20p-NPs (41% Sytox-positive).  In contrast, CDDP induced 
alterations in the membrane asymmetry (~9%) detectable by the violet ratiometric probe 
that was inhibited by Z-VAD-FMK (2.6%) or Bcl-2 (4.6%) (Figure 21B).  The 
combination treatment of CDDP followed by CT20p-NPs was effective with increased 
numbers of cells staining positive for both membrane asymmetry and Sytox uptake 
(~60% combined Sytox-positive). Caspase inhibition or Bcl-2 over expression minimally 
affected these results (~58% and ~47% combined Sytox-positive, respectively) (Figure 
21B).  These findings are suggestive that CT20p could engage a death mechanism 
distinct from that of CDDP that does not involve the intrinsic mitochondrial pathway, 




To determine CT20p was directly affecting mitochondrial physiology while 
triggering a non-apoptotic death mechanism, we examined cells for changes in the 
mitochondrial membrane potential (). Typically apoptotic activities result in 
depolarization or low (L) mitochondrial membrane potential.  We observed that 
mitochondria in MDA-MB-231 cells maintained a high (H) to intermediate (I) , that 
decreased to intermediate (I) levels upon treatment with empty NPs (results from 6 
hours of treatment shown; Figure 21C).  Note that empty NPs did not cause cell death 
(Figure 18).  In contrast, treatment with CT20p-NPs led to cells containing mitochondria 
with increased or high  (H) that did result in eventual cell death (Figure 21C). 
Hyperpolarization of the mitochondrial membrane is not characteristic of apoptosis but 
rather is associated with conditions that cause necrosis [106].  These results collectively 
suggest that the activity of CT20p, once delivered and released from NPs, triggers a 
series of intracellular events that may involve mitochondria but result in the eventual 
rupture of the plasma membrane and cell lysis more consistent with necrotic-like 
mechanisms. 
To demonstrate that CT20p was cytotoxic in situ, a small scale murine tumor 
experiment was performed. MDA-MB-231 cells were implanted in the flanks of nude 
mice and intra-tumoral or systemic injections of CT20p-NPs peptide were applied once 
tumors were detected (~9-17 mm). Intra-tumoral injections with performed twice over a 
period of week and complete tumor regression was observed (Figure 22A), as 
visualized in the representative ultrasound images (Figure 22B).  Systemic application 
of pegylated-CT20p-NPs was achieved with a single intravenous injection and tumor 
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regression was also observed (Figure 22A and 22B).  Mice were observed daily for two 
weeks after systemic treatments with CT20p-NPs and no signs of distress were noted.  
Upon dissection, tumors in mice that had received injections of CT20p-NPs were 
undetectable or liquefied, while organs (liver, kidneys, lungs) appeared normal and 
indistinguishable from control mice.  These results are indicative of the potential 
therapeutic application of CT20p-NPs.     
Discussion 
Our results revealed that the last 20 amino acid residues of the C-terminus of 
Bax bear striking similarity to AMPs. Indeed, the presence of cationic and hydrophobic 
residues, including double lysines, suggests that peptides derived from this C-terminal 
segment may have the capacity to promote cell death in the absence of an initiating 
death signal. In addition, the primary sequence of the C-terminal segment of Bax 
imparts a favorable degree of solubility to CT20p, allowing encapsulation in NPs for 
delivery to cancer cells. Introduction of CT20p-NPs into colon and breast cancer cells 
resulted in cell death that is independent of Bax expression and is not suppressed by 
over-expression of Bcl-2. Unlike the full-length Bax protein, CT20p appears to cause a 
lethal sequence of events that result in membrane rupture not characteristic of 
apoptosis. These observations suggest that CT20p has the ability to induce a necrotic-
like cell death that is distinct from apoptosis-inducing agents, such as DNA alkylating 
drugs. Thus, CT20p-NPs could serve as a potent cytotoxic agent for use in combination 
anticancer regimens together with conventional agents. 
 
75 
Our data suggests that the CT20p may function by forming pores in lipid 
membranes.  This data is bolstered by evidence from a collaborative biophysical study, 
demonstrating that the structure of CT20p in aqueous solutions was partially α-helical 
(C-terminus) and partially β-sheet (N-terminus). CT20p could form a pore with a novel 
structure composed of eight peptide molecules in a strand−turn−helix conformation 
resulting in an “α/β ring” (Tatulian et al., submitted). Such pores made by CT20p in 
zwitterionic and anionic lipid membranes caused the release of calcein from loaded lipid 
vesicles (Garg et al., submitted). In this same study control peptides did not form pores 
in lipid membranes that caused calcein release, indicating that the observed pore 
formation was specific to CT20p.  Second-order rate kinetics revealed that initial pore 
formation by CT20p was slow (involving 2−3 peptides), which was followed by a faster 
rate of assembly involving up to eight peptide molecules.  These studies led to a model 
of an octameric, trans-membrane pore with an inner diameter of 20−22 Å that could 
transport calcein, ions or slightly larger molecules (Tatulian et al., submitted). This data 
coupled with our observation that the CT20p can localize to mitochondria membrane 
systems in intact cells and cause the release of small molecules from mitochondrial-like 
lipid vesicles suggests that mitochondria may participate in the necrotic-like cell death 
we have observed. This implies that CT20p could form pores leading to the release of 
small ions or molecules sequestered in the mitochondria, consistent with mitochondrial 
membrane hyperpolarization. These events, in turn, could initiate a lethal cascade of 
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events causing the morphological changes and membrane rupture that we observed in 
cells treated with CT20p. 
A number of studies have focused on harnessing or regulating the activity of Bcl-
2 family members to induce the death of cancer cells. The poration activity of α-helical 
fragments from Bcl-2 proteins has been documented [107–109].  Such studies showed 
that peptides composed of the α5 and α6 helices of Bax could permeabilize 
membranes, forming channels that release sequestered contents like calcein [110], 
[111], providing insights on how the full-length Bax protein may function to permeabilize 
mitochondria and induce apoptosis. GFP-tagged versions of the α5 and α6 helices of 
Bax induced apoptotic cell death as indicated by increased annexin-V binding, PARP 
cleavage and caspase 3 activation, and, when fused to a cell-penetrating motif, caused 
regression of tumors [103].  In the same study, a GFP-tagged, longer version of the α9 
helix of Bax (as compared to CT20p) was tested and did not cause apoptosis [103].  As 
explanation, the additional residues added to the C-terminal sequence may add rigidity 
and impair the death-inducing activity we observed with the shorter CT20p. In fact, we 
previously examined a Bax C-terminal peptide that contained five additional residues 
(25mer) that was less effective inducing cell death when expressed in cells (data not 
shown). Other sequences from Bax that have been examined by others include the BH3 
domain. In peptide form, the Bax BH3 domain induced apoptosis when used to treat 
cells [112].  This was mostly due to the BH3 peptide blocking the interaction between 
Bax and anti-apoptotic proteins like Bcl-XL. The Bax BH3 peptide did not directly 
activate Bax or trigger the translocation of Bax to the mitochondria [112].  This study 
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and others have focused efforts on exploring the indirect use of BH3 peptides as 
inhibitors of anti-apoptotic proteins, such as Bcl-2, rather than as direct activators of cell 
death via membrane pore formation. The subsequent development and clinical testing 
of BH3-derived small molecule mimetics [113] is the direct consequence of 
demonstrating the therapeutic utility of peptides based on functional domains from Bcl-2 
proteins.   
CT20p shares many of the features of naturally occurring AMPs such as cationic 
charges (i.e., double C-terminal lysines) and portions of hydrophobic stretches.  This 
may promote selectivity for negatively charged membranes, like those of prokaryotes 
and also cancer cells. The membranes of cancer cells, because of increased exposure 
of phosphatidylserine (PS) [114], the presence of sialic acid residues linked to 
glycoproteins like mucins [115], and the altered expression of proteoglycans with highly 
negatively charged side chains [116], [117], tend to accumulate negative charges. Once 
attracted to membranes, AMPs can kill by necrotic (lysing cell membranes) or apoptotic 
(disrupting mitochondria) mechanisms. AMPs can also form pores; however, the 
structural features of these remain to be fully elucidated. A good model from which to 
compare the action of CT20p is the synthetic peptide, (KLAKLAK)2 (KLA peptide), made 
to replicate the amphipathic features of AMPs [118].  KLA peptide is poorly permeable 
to mammalian cells and requires fusion with a cell membrane penetrating agent to enter 
cells.  Most studies report that, once introduced into a cell, the KLA peptide (like CT20p) 
localizes to mitochondria [100].  Unlike CT20p, however, the KLA peptide causes 
depolarization of the mitochondrial membrane and apoptosis under most conditions 
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tested [101], [102], [119], [120].  Interestingly, a dose effect was observed when the 
KLA peptide was fused to prostate cancer antigen in that low doses caused apoptosis, 
while high doses led to necrosis [121].  We did not observe such effects with CT20p, 
which caused non-apoptotic cell death with cell lysis at all doses tested, with the major 
portion of experiments performed in the picomolar range.   
In summary, our results suggest that CT20p acts through a non-apoptotic 
pathway to induce cancer cell death and thereby has potential application with 
apoptosis-inducing agents in combination therapies to activate multiple death pathways. 
This is a potent approach to treat cancer in that the targeting of membranes, the rapid 
mode of action and the necrotic-like death pathway make CT20p an unlikely inducer of 
cancer drug resistance.  We demonstrated herein that CT20p can be encapsulated in 
polymeric NPs, which increases its bioavailability and enables delivery to tumor cells. 
We observed tumor regression under both intra-tumoral and systemic applications, 
suggesting that CT20p-NPs were accessing the tumor sites through tissue and through 
the blood. One explanation for this is that the leakiness of the tumor vasculature, the so-
called enhanced permeability and retention effect (EPR) [122], helped the CT20p-
loaded NPs accumulate within tumors. These results justify the next phase of testing 
using tumor-targeting nanoparticles for optimal delivery of CT20p in combination 
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Table 4. Comparison of CT20p with Anti-Microbial Peptides and Apoptosis-Inducing Peptides  
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                  GIGAVLKVLTTGLPALISWIKRKRQQ 46 5 alpha 
Brevinin 1 Frog                FLPVLAGIAAKVVPALFCKITKKC 66 4 unknown 
Ranalexin Frog                         FLGGLIKIVPAMICAVTKKC 65 3 alpha 
 
Cecropin A Insect 
        
KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK 
45 6 alpha 
Dermaseptin 
B2 
Frog   ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ 54 3 alpha 
Magainin 2 Frog GIGKFLHSAKKFGKAFVGEIMNS 43 3 alpha 
CT20p REV n/a                     GMKKWITLSATLVGAVFTIV 60 2 n/a 
KLA peptide synthetic         KLAKLAKKLAKLAK 57 6 alpha 
 
Bax a5-a6 Human    DGNFNWGRVVALFYFASKLVLKVPELIRT 52 2 alpha 
BIM BH3 Human                             MRPEIWIAQELRRIGDEFNA 40 0 unknown 
BID BH3 Human                    EDIIRNIARHLAQVGDSMDR 40 0 unknown 






Figure 16 Lysines in CT20p, which is Based on the C-terminus of Bax, Contribute to Intracellular 
Localization. 
(A-B) Mitochondrial translocation of HA-tagged wild type Bax (Bax-KK) and K189/K190 mutants, 
expressed in 293 cells using the Flp-In T-Rex system, was examined by immunoblot.  p38 MAPK and 
Prohibitin were blotted for cytosolic and mitochondrial content, respectively.  Data are representative of 
five independent assays.  Images from full-length blots were cropped for concise presentation. (C) The 
mitochondrial translocation of DD-tagged Bax full-length (FL-Bax) and DD-tagged CT20 peptides, wild-
type and EE, LL and RR mutants, was examined in Bax
+/+ 
HCT-116 cells by immunoblot.  Endogenous 
Bax was probed with anti-Bax antibody.  p38 MAPK and prohibitin indicated cytosolic and mitochondrial 
content, respectively.  DD-fusions were detected with an anti-DD antibody.  Controls are cells transfected 
with empty vector or untransfected. Data are representative of two independent assays. Images from full-









Figure 17.  CT20p causes the Release of Sequestered Contents from Mitochondrial-like Lipid 
Vesicles without Loss of Membrane Integrity. 
(A)  CT20p was commercially synthesized and calcein-loaded mitochondrial-like LUVs prepared. Calcein 
release from CT20p-treated LUVs was measured as described in Experimental Procedures. Red lines 
indicate maximal release of calcein with Triton X-100.  Blue lines indicate addition of LUVs and green 
lines (except for control) indicate treatment with CT20p or mutants. Dotted line is buffer alone.  CT20 is 
the wild-type peptide and CT20-LL and CT20-EE are mutations of the double lysines (K189/K190 in the 





                     
Figure 18.  CT20pe can be Encapsulated in NPs for Delivery to Cells. 
(A) Schematic representation of the three dimensional structure of aliphatic hyperbranched NPs.  (B) 
HCT-116 cells were treated with NPs loaded with DiI or DiI + CT20p (0.07 nM) for 24 hours.  Time-lapse 
movies were acquired as described in Experimental Procedures using a 10x air objective.  For each 




 HCT-116 cells were treated with 
NPs loaded with DiI at amounts of 5, 10 and 15 g for 24 hours and cell death was measured using Sytox 
AAD as described in Experimental Procedures.  Results or images are representative “snapshots” of 




                                   
 
Figure 19.  CT20p-NPs Kill Bax-containing or Bax-deficient HCT116 cells.   
(A-B)  Bax
+/+
 (A) and Bax
-/-
 (B) HCT-116 cells were treated with AM- or COOH-NPs loaded with CT20p 
(350 pM) for 24 hours.  To visualize mitochondria, cells were treated with MitoTracker Red 580 and time-
lapse movies were acquired as described in Experimental Procedures using a 63x Oil objective.  For 
each sample, three different fields of view were acquired.  Images are representative “snapshots” of three 
independent experiments. (C) HCT-116 cells were treated with CT20p-NPs (350 pM) and, after three 






Figure 20.  CT20p-NPs Kill Breast Cancer Cells. 
(A, C)  MCF-7 (A) or MDA-MB-231 (C) cells were treated with AM- or COOH-NPs loaded with CT20p 
(350 pM) for 24 hours.  To visualize mitochondria, cells were treated with MitoTracker Red 580 and time-
lapse movies were acquired as described in Experimental Procedures using a 40x Oil objective.  For 
each sample, three different fields of view were acquired. Images are representative “snapshots” of three 
independent experiments. (B, D) MCF-7 (B) or MDA-MB-231 (D) cells were treated CT20p-NPs (350 pM) 
and, after three hours, cell death was measured using Sytox AAD as described in Experimental 





Figure 21.  Mechanism of Death Mediated by CT20p is Effector Caspase Independent and 
Resistant to Bcl-2. 
(A) MDA-MB-231 cells were treated with COOH-NPs encapsulated with CT20p (350 pM) and treated with 
ZVAD-Fmk and/or CDDP as described in Experimental Procedures.  Cells were also transiently 
transfected with Bcl-2.  Cell death was assayed with Sytox AAD.  (B)  MDA-MB-231 cells were treated as 
described in (A) and membrane asymmetry measured with a violet radiometric probe.  Dot blots show a 
combination of results from Sytox (cell death) and changes in membrane symmetry.  Data shown is 






Figure 22.  CT20p Induces Tumor Cell Death in vivo. 
(A) MDA-MB-231cells were implanted in nude mice and changes in tumor volume assessed by 
ultrasound as described in Methods.  (D) Representative ultrasound image of tumor regression induced 





CHAPTER 4:  STABILIZATION OF THE TERTIARY STRUCTURE 
OF BAX IS DEPENDENT ON THE C-TERMINAL HELIX 
Introduction 
Molecular dynamics (MD) simulations of solved structures can give insight into 
the mechanism by which proteins fold, unfold and interact with the surrounding 
environment.  This is a particularly powerful tool in understanding the dynamic nature 
the Bcl-2 (B-cell lymphoma 2) family of proteins.  Despite the functional division of the 
family into pro- and anti- apoptotic proteins, the tertiary structure and arrangement of 
amphipathic helices around a core hydrophobic helix is maintained throughout [53]. 
Additionally, these proteins retain a hydrophobic groove that is required for dimerization 
events that regulate the balance between survival and cell death [3].  Mutations within 
this groove have a deleterious effect on dimerization and subsequent activity of the 
affected proteins [59]. 
  Bax, a member of the pro-apoptotic sub-family of Bcl-2 proteins, retains the 
characteristic helical packing and hydrophobic groove that are the hallmarks of this 
family.  The NMR solved structure [10] shows 9 alpha helices, of which the  helix, 
imbedded within the protein, is the most hydrophobic [123], [124].  Bax also has an 
extensive hydrophobic groove spanning one face of the protein, and is comprised of 
helices 2, 3, 4, and 5.  When Bax is in its cytosolic, monomeric form, the amphipathic 9 
helix resides within the groove, and upon conformational change, the helix dissociates 
from the groove allowing for oligomerization [124].  This conformational change is 
purported to allow for translocation of Bax to the mitochondrial membrane due to the 
 
88 
exposure of the C-terminal helix and relaxation of the bulk of the protein releasing the 
 helices [17], [50]. 
Molecular dynamics simulations of Bax, and most other Bcl-2 proteins, are most 
commonly performed in an effort to better design inhibitors or activators [41], [52], [53].  
Recently, however, a study of the stability of the protein under elevated temperatures 
revealed that the helix maintained its secondary structure at 500K despite the 
apparent melting of the surrounding helices [123].  This suggests that the application of 
appropriate force fields in a generated, controlled environment can yield information on 
the stability or weaknesses of micro-domains within the protein.  This information can be 
used to direct the generation of point mutations and deletion mutants of Bax to elucidate 
the mechanism by which it transitions from cytosolic to membrane bound form. 
Previous in silico studies in our lab suggest that it is energetically favorable for 
the  helix to bind in a reverse orientation in the hydrophobic groove.  In this 
orientation, the positively charged Lysine residues at positions 189/190 interact with the 
negatively charged glutamic acid and asparagine residues at positions 69 and 73 
respectively.  Analysis of the existing structure in comparison with selected mutations to 
residues 69 and 73 at the boundary of the hydrophobic groove will allow for a 
comparison of the global fluctuations in the tertiary structure of the protein, as well as 
localized distortions within the binding pocket.  Similarly analysis of the C-terminal 
deletion mutant will indicate whether the occupation of the groove by the  helix 
contributes to stability of the protein.  
 
89 
Currently, there is one solved structure of isolated Bax (PDB ID 1F16) [10], with 
the only other complete structure (PDB ID 2K7W) complexed with a BH3 peptide [125].  
The solution structure 1F16 is based on a purified protein expressed in E.coli and then 
isolated from the bacterial lysate with a cleavable N-terminal Chitin Binding Domain 
(CBD) [10].  This poses a challenge for accurate MD description of the behavior of the 
protein as proper folding of the N-terminus is essential for the maintenance of the 
inactive form of Bax [49].  Described within is a method by which an untagged, properly 
folded Bax and mutant variants can be expressed and purified in order to characterize 
the transition from monomer to oligomer.   
Materials and Methods 
Generation of Bax Mutants in Silico. 
Based on the existing PDB file generated from the solved NMR structure of Bax 
[10], groove mutants were generated within the Visual Molecular Dynamics (VMD 
version 1.9) program [126].  Briefly of the 20 models generated from the NMR structure, 
model 6 was isolated from the source PDB file 1F16.  This model was then used as the 
base model for subsequent deletions and point mutations.  The single and double 
mutations generated were selected to simulate a charge reversal on residues 69 and 
73.  Additionally a CT20 deletion mutant was generated to remove the C-terminal 20 
residues from full-length protein.  The mutations function within the analysis component 
of VMD allowed for the generation of single point mutations, once the residue was 
mutated in silico the X, Y, and Z coordinates of the source PDB file were used to 
generate a new point spread function to describe the orientation of the atoms in the 
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mutated residue and any other changes in orientation in surrounding atoms.  From this, 
VMD was directed to generate new PDB files containing the mutated residues.  
Molecular Dynamics Simulations. 
All MD simulations were carried out using GROMACS (GROningen MAchine 
for Chemical Simulation) version 4.5.5 [127], [128], and computations were carried out 
on the Stokes Advanced Research Computing Center (The University of Central 
Florida).  This was conducted in two steps.  First the PDB files generated in VMD were 
ported into GROMACS using the pdb2gmx command.  The protein was then placed in a 
box so that the distance between the protein and the edge of the box was 1.5 nm to 
satisfy the periodic boundary conditions.  Since periodic boundary conditions are 
applied to the system, long-range interactions in the box were calculated using the 
smooth particle mesh Ewald algorithm [129].  Then using the genbox program, the box 
was filled and the protein solvated with water using either the TIP3P or SPC/E water 
model [130], [131].  Any latent charge on the protein was neutralized by the addition of 
either sodium or chloride ions.  The applied force field for the generated topology used 
for these simulations was AMBER99SB-ILDN [132] because of the ability of the force 
field to describe torsional motion in side chains.  To ensure that the AMBER99SB-ILDN 
force field contained sufficient parameters to describe the effects of the programmed 
constraints on the protein, the same simulations were run applying different force fields 
to the system.  The force fields used were AMBER99SB [133], an less descriptive 
version of the AMBER99SB-ILDN force field, CHARMM27 [134], and OPSL-AA/L[135] 
all atom force field.  MD runs to equilibrate the system were conducted using the 
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grompp preprocessor to prepare the topology files to determine the energy minimization 
(EM), temperature (300K, or 300-500K), and pressure equilibrium (2 bar).  Once 
equilibrated, the position restraints were released and the production MD was run using 
a leap-frog algorithm to couple the position restraints with constant temperature and 
pressure [136] and data was collected.  Data from the simulations was then analyzed 
for variations. 
Analysis of Simulations.  
The data generated from the wild type and mutant forms of Bax were analyzed 
after each MD run.  The EM, temperature and pressure equilibration, density, root mean 
square deviation (RMSD), and radius of gyration were derived and plotted using 
GraphPad 5.  The effects of the MD simulation on the molecule were able to be 
visualized in VMD. 
Expression and Purification of the Full Length Bax Protein 
Full-length Bax cDNA with a HMM sequence: (ATG TGG TGG CGC CTG TGG 
TGG CTG CTG CTG CTG CTG CTG CTG CTG TGG CCC ATG GTG TGG GCC) was 
cloned into pcDNA6/His B vector for expression in mammalian system.  Sequencing 
was done to ensure that the ATG was on the HMM sequence and that the FL BAX was 
properly oriented in the vector.  293T cells were grown in T75 flasks in 20mL DMEM 
supplemented with 10% FBS and treated with 1% penicillin/streptomycin.  Cells were 
grown to 75% confluence before transfection.  
Cells were transfected according to Mirus LT1 protocol in complete DMEM. The 
cells were also treated with blastocidin to select for cells expressing the vector.  Stably 
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expressing cells were expanded into T75 flasks to maximize protein yield.  The cells 
were transitioned to a serum free media to facilitate the purification process.  Media 
from the flasks was collected every 48 hours and concentrated through 3kD 
concentrator down to 2mL volumes.  The media was then buffer exchanged with 20 mM 
Bis-Tris buffer supplemented with 50mM L-Glutamic acid and 50 mM L-Argenine at pH 
7 to prepare for ion exchange chromatography (IEX).  The protein was passed over a 
UnoQ anion exchange column (BioRad).  The protein was eluted with a Bis-Tris buffer 
containing 1M KCl and was collected for size exclusion chromatography (SEC). 
The eluted protein was then run through a de-salting column prior to SEC.  Bax 
was then run through a Superdex 200 (GE) size exclusion column using the Bis-Tris 
buffer from the IEX for elution (flow rate 0.10 mL/min).  The peak fractions were 
collected for analysis.  
SDS-PAGE and Western Blotting. 
Western blots on the Bax fractions were run at each step of the purification 
process using 12-15% SDS-PAGE gels, with the protein transferred to PVDF 
membranes and probed with N-20 (Santa Cruz), for endogenous Bax, this was followed 
by the appropriate secondary antibodies conjugated to horseradish peroxidase (HRP) 
and visualized with enhanced chemiluminescence kit (Pierce). Molecular weight 
markers (SeeBlue Plus 2 (Invitrogen)) were used to approximate the position of protein 




The ability for Bax to undergo conformational change during apoptosis is 
necessary for the protein to translocate to the mitochondria.  A thorough analysis of the 
wild type protein analyzed against the individual amino acid contribution of specified 
point mutations and C-terminal deletion mutant will provide insight into the regions of 
instability within the protein that may contribute to its transition state.  The findings of the 
molecular dynamics simulations yield important information as to the ability for mutant 
variations of the protein to function in a predicted manner, and therefore serve as a 
guide for the design of the expression system to purify Bax. 
Energy Minimization and Validation of Force Fields. 
The initial Bax structure, obtained from set of coordinates model 6 of the 20 
representative NMR structures was solvated, neutralized, then relaxed through energy 
minimization using the GROMACS MD engine, mdrun.  This is necessary prior to 
running a production MD to ensure that the applied force field adequately describes the 
system.  The minimization process allows for the determination of the potential energy 
(Epot), which is measured in kJ/mol.  For the energy minimization to be considered 
successful the graph of the potential energy should converge and the value on which it 
converges should be negative.  An analysis of the potential energies of 1F16 (WT Bax), 
the groove mutants (E69R, N73R, and E69R,N73R), and the C-terminal deletion mutant 
(DCT) (Figure 23) show that the applied force field, AMBER99SB-ILDN, is sufficient to 
describe the system as all structures converged and were negative with values ranging 
between -2.0x106- 11.85x106 kJ/mol.  The initial stability of the structure is linked to the 
potential energy in that the lower the Epot the more stable the structure is prior to the 
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dynamics run.  Based on an analysis of the Epot for each structure, the least stable is the 
DCT and the most is the N73R mutant.   
As stated previously, the applied force field for these simulations was the 
AMBER99SB-ILDN force field.  This was chosen in part because of the refinement of 
the AMBER99SB protein force field.  The force field better describes 1 torsional 
potentials determined by rotation about the angle [132]. This allows for a better 
assessment of the contribution from the torsional energies over the AMBER99SB force 
field, and more completely describes the protein energetics.  Because of this, the 
AMBER99SB-ILDN provides a better description of the contribution of point mutations to 
the stability and structure of the system.   
The Validity of this force field on the system was tested by evaluating and 
comparing the Epot of the WT Bax and DCT models minimized with different force fields 
applied to the system.  The tested force fields were CHARMM 27, AMBER99SB, and 
OPLS-AA/L, and the Epot for WT Bax and DCT under each force field was compared for 
variation (Figure 24).  Based on the energy minimization, the CHARMM27 force field is 
a not suitable for this system as determined by the difference in Epot compared to the 
other force fields.  This is expected because CHARMM27 is optimized for describing 
nucleotides and small peptides [134].  The Epot for the structure as described by the 
AMBER99SB force field is comparable to that of the AMBER99SB-ILDN also as 
expected since the only significant difference is the inclusion of the contribution of the 
1 torsional potential by the ILDN variation.  There was a measurable, but acceptable 
difference in the Epot when the OPLS-AA/L force field was applied to the structure.  The 
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energy minimization was calculated to be the lowest with this force field, despite the fact 
that is very similar to the AMBER force field.  The difference lies in the AA portion of the 
OPLS parameters includes all of the atoms explicitly [135].  There also may be a 
contribution of the water model to the energy of the system as the SPC/E water model 
was used instead of the TIP3P water model.  The potential for the TIP3P model is 
represented as such: 
    ∑∑
      
   




   
   
 
   
 
    
 
   
Where qi and qj partial charges, rij is the distance between charged sites (the oxygen 
atoms in the water molecules), and A and B are the Lennard-Jones parameters [130].  
In the SPC/E water model, the potential is adjusted to correct for the dipole moment on 
a polarized water molecule: 









This allows for a more accurate representation of the contribution of water to the 
system, and its effects on the structure [130]. 
MD Simulations and Analysis of Protein Stability. 
MD simulations conducted within GROMACS show movement of the structures 
over time and under constant temperature and pressure.  The constrained atomic 
positions were released and the protein was allowed to move freely for 10ns.  The initial 
runs on the WTBax, the groove mutants and the DCT were run at 300K and 2 bar 
pressure.  Figure 25 shows the radius of gyration of the each structure.  The gyration, or 
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general movement about the center of the protein, is an indicator of the stability of the 
structure over time.  All mutations were relatively stable as indicated by the relatively 
static movement, with the exception of DCT which began to fluctuate greatly as the 
simulation progressed.  A calculation of the root mean square deviation (RMSD) of each 
structure shows (Figure 26) that, relative to the original positions, there is very little 
movement, again with the exception of DCT.  The increase in the RMSD corresponds 
with the increase in the radius of gyration in the simulation indicating that the deleted C-
terminus was conveying some stability to the overall structure.  
In order to further probe the contribution of the C-terminus to the overall stability, 
the protein was subjected to a series of temperature increases.  This melt study was 
conducted using the OPLS-AA/L force field and validated in the other force fields 
described above.  The temperature intervals were 300K, 400K, and 500K, and both 
WTBax and DCT were subjected to these conditions.  Figure 27 shows the modeled 
structures at each temperature with the applied trajectories from each simulation.  The 
structures were visualized in VMD.  The WTBax was able to retain its secondary 
structure as the protein was melted.  This is particularly evident in the maintained 
helicity of the hydrophobic core ( helix).  This corresponds to the findings in a 
previous study that reported that the core stability of Bax lies in the helix [123].  To 
determine if the absence of the C-terminus would affect the stability of the protein the 
same conditions were applied to the DCT structure.  The absence of the C-terminal 
helix has a dramatic effect on the stability of the protein as the protein lost a majority of 
its secondary structure with each increase in temperature.  A look at the change in the 
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RMSD (Figure 28) verified that WTBax is a far more stable structure than its DCT 
derivative.   
Protein Expression. 
One of the challenges to studying Bax is that, because its activity is regulated 
through the proper folding of both the N- and C- termini, expressing the protein with a 
terminal tag may affect the activity.  To combat this, a novel expression scheme was 
developed.  Rather than expressing the protein in bacteria, the protein was expressed in 
293T cells with a cleavable synthetic secretion sequence attached to the N-terminus.  
This sequence was derived from Hidden Markov Modeling of known native secretory 
sequences [137].  The addition of this sequence allows Bax to be directed to the 
endoplasmic reticulum and then shuttled out of the cell.  Figure 28 shows that Bax is 
contained in the media as shown by coomassie stain and western blot (Figure 28A).   
The concentrated protein from the media was then run through a size exclusion 
column.  Based on the dimensions of the column and the pores of the resin, a protein of 
Bax’s size (22kD) is expected to elute off of the column at approximately 17mLs.  An 
analysis of the absorbance at 280 shows a very intense peak that apex is at ~17.8mLs 
(Figure 28B). The presence of Bax in this fraction was verified again by western blot 
(Figure 28C). The recovered protein from the purification can now be assessed for 
function and also, depending on purity, for structure.   
Discussion 
Within the Bcl-2 family there is a conserved series of structural motifs and 
functional homology [3].  Since Bax is dynamic in that it has a cytosolic and membrane 
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bound form, any insight into what regulates the transition can be leveraged into the 
design of inhibitors or activators to manipulate the protein function.  The molecular 
dynamics approach used in this study examines the contributions of functional domains 
and specific residues on the stability of the overall structure.  These simulations indicate 
that helical packing about the about the hydrophobic core is dependent on the 
occupation of the hydrophobic groove.  In the absence of the C-terminus the protein 
relaxes compared to the wild type protein.  This relaxation would allow for membrane 
docking as the relaxed structure would expose hydrophobic region to lipid membranes. 
Validation of the in silico modeling with expressed, purified Bax and Bax mutants 
can ultimately elucidate the mechanism of action by which the protein makes its 
transition to the membrane and adopts its oligomeric form.  While this work is 
incomplete, the simulations component alone gives a good deal of information regarding 
the stability of various mutants, and also illustrates the need for additional structural 
studies, particularly a resolved structure of Bax that is not obtained from a tagged 
expression of the protein.  Since most molecular dynamics simulations of Bcl-2 family 
members seek to determine binding partners for the design of inhibiting or activating 
compounds and peptides, the solved structure of the protein must be accurate.  
Additionally, the generation of pure, properly folded Bax can be used in a variety of 
biophysical and molecular biology approaches to determine structural and functional 




Figures and Tables 
 
 
Figure 23. A Comparison of the Energy Minimization of Bax Variants. 
The energy minimization of WTBax and four mutant varients were compared.  The Epot is calculated in 
kJ/mol and is used as a measure of the stability of a system.  Convergent curves indicate that the applied 
force fields are correct.  The more negative the Epot the more potential energy the system has at the onset 
of the simulation. 
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Figure 24. Validation of the AMBER99SB-ILDN Force Field. 
Validation of the AMBERSB99-ILDN force field was conducted by running the WTBax model system 
through an energy minimization.  The validation force fields chosen were a less descriptive AMBERSB99, 
a more descriptive OPLS-AA/L, and a non-descriptive CHARMM 27 force field. 
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Figure 25. Radius of Gyration Indicates Stability of the Structure in the System. 
Radius of gyration about the center was measured for each structure.  The linearity of the plot for each 
structure is indicative of the stability of the protein in the system.  Variations in the linearity, as seen in the 





Figure 26. Root Mean Square Deviation of the Structure as Compared to the Initial PDB File. 
The RMSD of each structure was calculated for the atomic positions after simulation as compared to the 
initial atomic position from the PDB file.  The linearity correlates to the stability of the structure.  Variations 





Figure 27. Structural Changes as a Result of Increase in Temperature 
Visualization of the protein after simulation at each time step shows significant difference in the 
secondary structure.  Alpha helices are denoted in purple, light blue indicates an elongated or random 





Figure 28.  RMSD of WTBax and DCT at Each Temperature Step. 
RMSD calculations for both WTBax and DCT were measured for each temperature step.  The RMSD is 
measured in nm from the original position.  Increase in RMSD correlates to protein instability.  The 





Figure 29. Verification of the Presence of Bax from the Mammalian Expression System. 
(A) Coomassie stain of Bax in DMEM media after expression and secretion in 293T cells.  Bax was 
detected by western blot in this sample.  (B) Concentrated protein was run through a size exclusion 
column and the peak fraction was collected.  (C) Western blot analysis of peak fraction proteins shows a 




CHAPTER 5: CONCLUSION 
The results presented in the preceding chapters describe a previously 
unrecognized role for the pro-apoptotic protein known as Bax in the regulation of 
bioenergetics.  This observation prompted further exploration into the structure and 
function of Bax.  These studies have revealed that the C-terminal helix retains the ability 
to translocate to the mitochondria and can promote a non-apoptotic cell death.  These 
results are consistent with data from structural studies of full-length, untagged Bax 
which show that the C-terminal trans-membrane domain plays a key role in the overall 
stability of Bax.  When taken together, these results have laid the groundwork for 
additional studies on Bax structure and function and have shed light on a viable path 
towards developing new therapeutic agents to modulate Bax activity.   
During embryogenesis, Bax plays a crucial role in normal tissue development; 
the absence of Bax/Bak either results in death in utero, or severe developmental 
defects, usually involving an abnormal accumulation of cells [138].  Classically 
described as a killer protein, overexpression of Bax in cell culture leads to mitochondrial 
membrane disruption and propagation of the apoptotic signal.  Like many of the Bcl-2 
family members, Bax is a target for drug design because of its role in apoptosis.  Efforts 
to design drugs to activate Bax, particularly in cancer cells, have been met with limited 
success.  Attempts to understand the mechanism of Bax translocation and poration of 
the mitochondria have had limited success. 
The dynamic functionality of the protein is apparent from the determination that 
Bax has a supporting role in mitochondrial energy production.  While a majority of the 
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protein does reside in the cytosol in the absence of an apoptotic signal, there is a 
detectable amount of Bax at the mitochondrial membrane.  The mechanism by which 
Bax contributes to the maintenance of bioenergetics in the cell remains to be elucidated.  
However, it was determined that this non-apoptotic function was not dependent on the 
C-terminus, and the effect could be diminished by over-expression of Bcl-2.  This 
discovery indicates that modulation of Bax activity, or its interactors in this yet to be 
described mechanism can skew the cell’s bioenergetics to either a glycolytic or 
oxidative phosphorylation state.  With Bax being reported to bind to voltage regulating 
proteins at the mitochondrial membrane interface, exploring these interactions is the 
most reasonable direction to pursue in an attempt to elucidate a mechanism for this 
previously undescribed, non-apoptotic function.   
To utilize Bax therapeutically, particularly in cancer, the classical approach has 
been to activate it using small molecules or peptides to bind to the BH3 region and force 
the conformational change into the active form.  Furthermore, peptides derived from 
Bax are typically used to tease out the function of the whole protein, but not as therapy.  
Examination of the C-terminus of Bax, the putative membrane binding domain of the 
protein, reveals that it bears many of the features of antimicrobial peptides.  Herein is 
the discovery that the CT20p, derived from the C-terminus conveys cytotoxicity to cells 
through a non-apoptotic mechanism.  The membrane binding region, when isolated and 
delivered into the cell, triggers a series of events that are quantifiable, but do not 
correspond with classical apoptotic events such as the activation of caspases.  This 
unique characteristic offers a therapy that is potent with limited off target effects 
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because the therapeutic target is negatively charged membranes such as the 
mitochondrial membrane.  The CT20p also increases the sensitivity of cells towards 
existing chemotherapies, indicating that the peptide is a sensitizer that can be used in 
combination therapy.  While the true mechanism of the peptide is not described here, 
further examination of how the peptide conveys cytotoxicity will help to direct the design 
of more potent membrane disrupting peptides, which can prove to be more effective 
than commonly used chemotherapies in the treatment of certain cancers. 
These two discoveries on the function of Bax lead back to a poor understanding 
of the structure and the ability of the protein to self-regulate.  The bio-energetic function 
is not dependent on the C-terminus outside of the specific targeting to the mitochondria.  
Likewise, the cytotoxicity of the CT20p is not dependent on the other putative 
membrane binding regions of the protein.  The contribution of computational modeling, 
in an effort to understand the molecular dynamics of Bax, yields vital information in 
terms of regions of instability.  Also, it indicates the generation of a deletion mutant may 
not result in a protein that functions as anticipated.  These discoveries underscore the 
need to re-examine the way that Bax behaves, and precisely how the conformational 
change is regulated.  Without a clear understanding of the means by which Bax is 
regulated, the potential utility of these discoveries loses value.    
The therapeutic mechanisms behind the manipulation of Bax regulation are often 
overlooked possibly because the protein is characterized in the literature solely as a 
driver of apoptosis.  As a result, the typical techniques, such as generating deletion 
mutants or isolating regions to study Bax components are not as informative as they 
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could be because success of the manipulation is measured in terms of activation of the 
intrinsic apoptotic cascade.  A thorough examination of how the Bax structure changes 
in response to environmental cues could yield insight into its oligomerization and 
membrane binding activities.  The preliminary success of the CT20p is because it was 
isolated not to study how it functions as part of Bax, but rather to see if it could retain its 
membrane binding ability absent of the rest of the protein.  The potent cytotoxic effect of 
the peptide alone opens up a series of questions involving the evolution of Bax and the 
evolutionary, endosymbiotic relationship of the mitochondria in the cell.  Computational 
modeling of the behavior of the protein in the presence and absence of the C-terminus 
yields insight into how Bax may have adapted to modulate its interactions with the 
mitochondria. 
Collectively, this work brings to the field a novel, homeostatic function of Bax 
through the activation of a small fraction of the monomeric, cytosolic Bax under non-
apoptotic conditions.  Because of this, inhibition of Bax may be used to sensitize a cell 
to nutrient deprivation or chemotherapies by forcing the cell into a certain metabolic 
state.  The last 20 residues of the C-terminus of Bax are not required for this function, 
but do contain a number of features characteristic of antimicrobial and membrane 
disrupting peptides.  As such, the CT20p derived from these residues is able to convey 
cytotoxicity in the absence of death signals, and this cytotoxicity appears to be 
independent of the apoptotic machinery.  Additionally these terminal residues may also 
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